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ABSTRACT 
 
Eukaryotic DNA topoisomerase I (Top1) is a highly conserved enzyme that 
functions to manage the torsional strain of DNA during cellular processes such as 
transcription, replication, chromatid condensation and recombination. The enzyme binds 
duplex DNA and through a series of strand cleavage and religation reactions removes 
positive or negative supercoils relieving torsional strain. Top1 is the sole cellular target of 
the anticancer agent camptothecin, which stabilizes the covalent complex. CPT 
cytotoxicity is S-phase dependent. It has been suggested that the mechanism of this S-
phase toxicity is due to the advancing replication forks either colliding with the stabilized 
drug-enzyme-DNA intermediate or colliding with positive supercoils that accumulate in 
front of the advancing forks leading to S-phase dependent lesions, inhibition of DNA 
replication and cell death. Despite extensive study, the exact events leading to cell death 
or repair of these lesions have yet to be defined. 
Using the genetically tractable budding yeast, S. cerevisiae, as a model system, a 
genetic screen was designed to isolate conditional temperature sensitive mutants that 
exhibit enhanced sensitivity to the CPT mimetic, Top1T722A. This genetic screen 
identified several recessive mutants (tah mutants) involved in a variety of cellular 
pathways including CDC45, DPB11, TAH11, which encode essential products for DNA 
replication and UBC9, which encodes an E3 SUMO ligase. 
The tah mutant cdc45-10 has a single amino acid substitution (G510R). These cells 
are hypersensitive to Top1T722A and transiently accumulate in early S-phase when 
shifted 36˚C due to a defect in Okazaki fragment maturation. These cells also exhibit a 
v 
slow growth phenotype when a component of the DNA damage checkpoint, RAD9, is 
deleted and is synthetically lethal with another tah mutant dpb11-10 at 36˚C suggesting 
that cdc45-10 exhibits defects in DNA replication. To understand how Cdc45 functions 
to protect cells against Top1-induced DNA damage, the defects in cdc45-10 were 
characterized. 
We identified cdc45-10 as a hypomorphic allele and increased gene dosage of this 
mutant allele restored cell viability in the presence of Top1T722A at 36˚C, however, 
increased gene dosage failed to restore cell viability to the cdc45-10,dpb11-10 double 
mutant strain suggesting that the defects in cdc45-10 that specific to Top1T722A 
sensitivity are distinct from the defects in the synthetic interaction of cdc45-10 and 
dpb11-10. These two distinct functions of Cdc45 were supported by results obtained from 
further characterizing the defects in cdc45-10 using a dosage suppressor screen to 
identify extragenic suppressors that complement cdc45-10 cell sensitivity to Top1T722A 
and our attempts to epitope tag Cdc45 and cdc45-10.  
The cdc45-10 defects in origin firing and replication fork progression were 
characterized by isolating replication intermediates and resolveing them using 2-D gel 
electrophoresis.  
Severeal lines of evidence including our report that cdc45-10 is hypersensitive to 
the antibiotic rapamycin (RAP), suggests a role for TOR signaling in S-phase. To 
investigate this possibility we isolated replication intermediates that were treated with 
MMS, RAP, HU or combinations of these drugs and origin firing and replication fork 
progression was visualized using 2-D gel electrophoresis.  
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CHAPTER 1: INRODUCTION 
 
1.1 EUKARYOTIC DNA TOPOISOMERASES 
DNA topoisomerases are responsible for managing the topological state of DNA 
in a cell. Due to the double helical nature of DNA, topoisomerases are needed for 
processes such as transcription and recombination, in which two strands of the helix must 
separate temporarily, or replication, in which the two strands separate permanently (1,2). 
There are two subfamilies of DNA topoisomerases: type I enzymes cleave a 
single strand of DNA, while type II enzymes cleave both strands of the DNA duplex to 
generate a double-strand break (1,2). Type I enzymes are further divided into IA and IB, 
where IA enzymes link the protein to a 5’ phosphate and relax negatively supercoiled 
DNA, while IB enzymes link the protein to a 3’ phosphate and relax both positively and 
negatively supercoiled DNA (1,2).  Type IA enzymes promote passage of the intact 
strand through the broken strand, while type IB enzymes leave the broken strand free to 
rotate around the intact strand (3). Type II enzymes are also organized into two families, 
Top IIA and Top IIB. All type II enzymes require ATP binding and hydrolysis to 
facilitate catenation or decatenation of duplex DNA. Top II enzymes are essential in all 
cells for segregation of chromosomal DNA after DNA replication and before cell division 
(3). 
DNA topoisomerase I (Top1), a type IB enzyme, is highly conserved from yeast 
to human in sequence and domain structure, reaction mechanism and camptothecin 
sensitivity. In higher eukaryotes, Top1 is essential as TOP1 knockout mice die early 
during embryogenesis (4). In the budding yeast Saccharomyces cerevisiae TOP1 is 
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nonessential, although top1 null mutants show a slight growth defect at lower 
temperatures and increased recombination at rDNA loci (5). As diagrammed in Fig. 1.1, 
Top1 contains four domains:  an unstructured, poorly conserved, nonessential N-terminal 
domain, a highly conserved core domain that binds DNA, a poorly conserved linker 
domain and a conserved C-terminal domain that contains the active site tyrosine (1). As 
shown in Fig. 1.2, Top1 is a monomeric enzyme that forms a protein clamp around 
duplex DNA. The enzyme transiently cleaves a single DNA strand when a 
phosphodiester bond in the DNA undergoes nucleophilic attack by the active site tyrosine 
to generate a phosphotyrosyl linkage between the enzyme and the 3’ phosphate of the 
nicked DNA. The noncovalently bound end of DNA is free to rotate around the 
covalently held strand relieving torsional strain and changing the linking number of 
DNA. In a second transesterification reaction, the nick is religated and the covalent 
enzyme-DNA complex is resolved (5). 
Studies in yeast and mammalian cells have identified Top1 as the sole cellular 
target of the anticancer drug camptothecin (CPT). Early studies using yeast strains 
deleted for TOP1 showed cells were resistant to CPT while the introduction of a plasmid 
expressing human or yeast TOP1 into these cells restored CPT sensitivity (6). 
Camptothecin was isolated from the bark of the Chinese tree, Camptotheca acuminata 
(4). Animal studies showed that camptothecin exhibited potent antitumor activity against 
a broad spectrum of tumors, however, in the early 1970s clinical trials were discontinued 
due to toxicity (4,7). CPT reversibly stabilizes the covalent Top1-DNA intermediate and 
inhibits the religation step of the catalytic cycle. Stabilized covalent intermediates can be 
formed in every stage of the cell cycle. Analysis of replication intermediates using the  
2 
  
Fig. 1.1 DNA topoisomerase I 
DNA Top1 is highly conserved from yeast to human. It has a nonessential N-terminal 
domain, a core domain that forms a protein clamp around duplex DNA, a poorly 
conserved linker domain and a conserved C-terminal domain that contains the active site 
tyrosine (Tyr727 in yeast and Tyr723 in mammalian cells).  
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Fig. 1.2 Catalytic cycle of eukaryotic DNA topoisomerase I 
DNA Top1 is a monomeric enzyme that forms a protein clamp around duplex DNA, first 
noncovalently, then covalently by nicking a single strand of the DNA and forming a 
phosphotyrosyl linkage with the 5’end leaving the 3’ end free to rotate around the 
covalently held strand unwinding the DNA. After rotation, the nick is religated and the 
enzyme and DNA dissociate.  The anti-tumor drug CPT stabilizes these covalent 
complexes and advancing replication forks collide with these drug-enzyme-DNA 
complexes resulting in irreversible DNA lesions that cause S/G2 arrest, inhibition of 
replication and cell death. Mutations in the Top1 protein change the catalytic activity of 
the enzyme. Substituting Asn 726 for His results in a Top1 enzyme that exhibits an 
increase in the rate of DNA cleavage without changing the rate of religation. Mutating 
Thr 722 to Ala results in an enzyme that is defective in religating the cleaved DNA 
strand, mimicing the cytotoxic action of CPT.  
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SV40 cell-free replication system showed that collision of the replication fork and TOP1 
cleavable complexes leads to three distinct events:  the formation of a double strand break 
at the fork, irreversible arrest of replication fork movement and formation of an 
irreversible TOP1-DNA covalent adduct leading to S-phase specific cell death and arrest 
in G2 phase of the cell cycle (7).  
More recent single molecule studies of human Top1 suggest an alternative 
mechanism for CPT induced cell death whereby drug binding of the CPT analog 
topotecan to Top1-DNA complexes induces accumulation of positive supercoils in front 
of moving replication forks. These local domains of high superhelical density would 
block fork progression, resulting in fork collapse and lethal DNA lesions that induce cell 
death (8).  
Since Top1 was identified as the cellular target of CPT, several water-soluble 
derivatives have been developed including topotecan and the prodrug irinotecan. There 
are several properties that make the camptothecins unique. First, identification of Top1 as 
the cellular target in yeast and mammalian cells: yeast cells deleted for Top1 are resistant 
to CPT and in vertebrate cell lines, single point mutations exist that render Top1 resistant 
to CPT. Second, within minutes of exposure, CPT can penetrate vertebrate cells, target 
Top1 and reversibly bind to Top1 cleavable complexes. Third, micromolar drug 
concentrations of CPT and its derivatives are needed to detect trapped Top1 cleavable 
complexes in biochemical assays suggesting camptothecins have a low affinity for Top1 
cleavable complexes (4). 
The amino acids located immediately N-terminal to the active site tyrosine are 
highly conserved between yeast and human enzymes. Several amino acid substitutions of 
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these residues have been reported to affect CPT sensitivity and enzyme catalysis (5). For 
example, in yeast or human Top1, substituting the two residues preceding the active site 
Tyr to Arg and Ala rendered the enzymes resistant to CPT. Biochemical studies indicated 
no difference in enzyme specific activity, however, in DNA cleavage assays the mutant 
enzymes exhibited diminished levels of CPT stabilized covalent complexes. These results 
suggest the levels of drug-stabilized enzyme-DNA complexes correspond with the 
cytotoxic activity of CPT in cells expressing the mutant enzymes (5). 
Substituting Ala for Thr 722 in yeast or the corresponding residue in human Top1 
creates an enzyme that mimics the action of CPT by increasing the stability of the 
covalent enzyme-DNA intermediate.  The mutant enzyme was catalytically active, yet 
exhibited a defect in DNA religation, yielding higher concentrations of covalent 
intermediates (5). 
Mutating the Asn immediately preceding the active site Tyr to different amino 
acids effects various aspects of Top1 function. Substituting Asn with Leu or Asp reduces 
the specific activity of the enzyme and reduces enzyme sensitivity to CPT. In contrast, 
mutating Asn to Ser or His had little effect on the specific activity of the enzyme. 
However, the Ser mutation rendered the enzyme resistant to CPT while the His mutation 
enhanced enzyme sensitivity to CPT and increased the rate of DNA cleavage (5). 
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1.2 EUKAYROTIC DNA REPLICATION 
 
1.2.1 Origins and ORC 
Eukaryotic cell division is a multi-step process where cells must faithfully 
replicate the entire nuclear content of DNA once and only once per cell cycle to maintain 
genomic integrity and chromosome ploidy (9). Timely duplication of DNA is 
accomplished when cells initiate replication from hundreds or even thousands of origins. 
The genetically tractable yeast system has been central in understanding the temporal 
order of events that must occur for cells to faithfully replicate DNA. In yeast initiation 
occurs at Autonomously Replicating Sequences (ARS) sequences that are distributed 
widely throughout the genome and fire in a temporally regulated pattern (10). Origin 
structure varies from species to species. S. cerevisiae origins are defined blocks of 
sequences approximately 100-200 base pairs in length (11). ARS elements are A/T rich 
regions that contain an 11bp consensus sequence (5’-(A/T)TTTAT(A/G)TTT(A/T)-3’) 
(9). This ARS consensus sequence (ACS) and immediate flanking sequences are called 
domain A. This domain is essential as deletion or mutation completely abolishes ARS 
function and is a unique identifier of replication origins (11). However, domain A itself is 
not sufficient for ARS activity. Sequences flanking domain A, domain B and C, 
contribute to ARS function. Domain B consists of sequences 3’ to the T-rich strand of the 
ACS and enhances the efficiency of origin utilization while domain C consists of 
sequences 5’ to the T-rich strand (9). 
Variations in efficiency and timing exist among origins. The temporal pattern of 
origin firing is such that origins are licensed to fire in late G1-phase. However DNA 
7 
synthesis is not initiated until S-phase when additional proteins are recruited to the 
origins as a consequence of Dbf4-dependent kinase and the cyclin-dependent kinase 
activity (discussed in detail below). These two kinases act on converging pathways to 
allow fail-safe activation of origins in S-phase and simultaneously prevent re-licensing of 
an origin (10). Strong or efficient origins fire in most S-phases while weak or inefficient 
origins fire only if replication is delayed. Early origins fire at the onset of S-phase while 
late firing origins are activated by Clb5/Cdk in late S-phase to complete DNA synthesis 
(10). Cryptic origins are those that only fire in S-phase when replication has been 
interrupted. For example, the cryptic origin, ARS301, fires in Rad53 defective strains 
exposed to DNA damaging agents (12) 
The six-subunit origin recognition complex (Orc), consisting of Orc1-6, was one 
of the first origin binding protein complexes identified and remains bound to the origin 
throughout the cell cycle. Orc is highly conserved in eukaryotes and archaea and is a 
sequence specific binding protein complex that recognizes the core sequence of the 
origin. Orc binds to active replication origins as well as transcriptional silencers, 
telomeric DNA and cryptic origins, suggesting that it may act as a landing platform for 
other chromosomal proteins (10). 
 
1.2.2 Pre-replicative complex formation 
To ensure that each origin fires once and only once during each S-phase, origin 
function is regulated in two discreet steps:  pre-replicative complex (pre-RC) formation in 
G1-phase of the cell cycle and initiation of DNA replication in S-phase, as shown in Fig. 
1.3. In G1-phase, pre-RC formation involves the sequential binding of Cdc6, Tah11 
8 
  
Fig. 1.3 DNA replication 
At the end of mitosis a decrease in Cdk-Clb kinase activity allows pre-replicative 
complex formation consisting of Orc, Mcm2-7, Tah11 and Cdc6. Cells pass through 
“START” in G1-phase committing them to DNA replication. As cells begin to transit 
from late G1 to S-phase, Dbf4-Cdc7 and Clb5/6-Cdc28 protein kinases become active 
and phosphorylate components of the pre-RC promoting the recruitment of Cdc45 and 
GINS.  Once DNA replication is initiated, Dpb11 recruits Pol ε and facilitates the switch 
between Pol α and Pol ε. Mcm2-7, GINS and Cdc45 move with replication forks as 
elongation occurs. 
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(Cdt1), and the Mcm2-7 complex to the Orc bound origin (13). Cdc6 and Tah11 first bind 
to Orc, Orc and Cdc6 then hydrolyze ATP to promote loading of Mcm2-7 on the DNA. 
The contribution of Tah11 in this process remains unclear. Cdc6 is phosphorylated upon 
origin activation by the cyclin dependent kinases (CDK), Dbf4-Cdc7 and Clb5/6-Cdc28, 
leading to protein degradation or nuclear export restricting its activity to the G1/S-phase 
of the cell cycle. Cdt1 (Tah11) is regulated in metazoans when geminin binds Cdt1 and 
prevents its activity in G2-phase or mitosis (10). The Mcm2-7 complex has a hexameric 
ring structure that is highly suggestive of a replicative DNA helicase. In S. cerevisiae, 
Mcms cycle in and out of the nucleus during the cell cycle. In other organisms they are 
located in the nucleus throughout the cell cycle, but binding to chromatin only occurs 
during G1/S-phase. In all eukaryotes, the Mcm2-7 complex is dislodged from the 
chromatin to move with replication forks. Assembly of Orc, Cdc6, Tah11, and Mcm2-7 
at the origin completes the pre-RC, effectively licensing the origin for DNA replication in 
the subsequent S-phase (10). 
For licensed origins to initiate DNA replication, however, they must pass through 
the G1 decision point, called START, which irreversibly commits the cells to a new 
round of cell division. START is properly executed when Cdc28, a cyclin dependent 
kinase, becomes active by forming a complex with Cln1/2. Nine cyclins modulate Cdc28 
activity: three G1 cyclins, Cln1-3, which are required for the passage through START 
and six B-type cyclins, Clb1-6, which are involved in S-phase and mitotic progression. 
The G1 cyclins are those that act on the pre-RC and lead directly to the initiation of DNA 
replication (9). Early studies showed that any of the three Cln proteins could compensate 
for the loss of another without affecting START. However, there are different functions 
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of Cln1-3.  Cln1 and Cln2 are highly similar proteins, whose expression is cell cycle 
regulated with levels peaking in late G1. Cln3 is less similar to Cln1 and Cln2 and is 
constitutively expressed throughout the cell cycle. Cln3 is responsible for activating the 
transcription of select genes in late G1 phase, including CLN1 and CLN2. Induction of 
these transcripts leads to an increase in Cln1/2-Cdc28 kinase activity, which catalyzes 
most or all of the events associated with START (9). 
Cln1/2-Cdc28 kinase activation is required for DNA replication to occur, however 
it is the B-type cyclins, Clb5 and Clb6, which directly activate origin firing. Clb5/Clb6-
Cdc28 complexes are formed in late G1-phase, but are kept inactive by the CDK inhibitor 
Sic1.  Sic1 has two functions in the cell cycle. First, it contributes to the shut off of the 
mitotic form of the Clb-Cdc28 kinase promoting the exit of a cell from mitosis. Second, 
Sic1 regulates the activity of Clb5/6-Cdc28 kinase, thereby controlling the timing of S-
phase.  A primary function of Cln1/2-Cdc28 is to target Sic1 for degradation to promote 
entry into S-phase. It was shown in wild-type cells that Sic1 accumulates in late mitosis, 
is phosphorylated at START in a Cln-dependent manner and is degraded shortly before 
S-phase. Sic1 degradation is dependent both on Cdc34, an ubiquitin-conjugating enzyme, 
and on the Cln-Cdc28 kinase. Following the down regulation of Sic1, the Clb5/6-Cdc28 
kinase is activated (9). 
A second protein kinase, Dbf4-dependent kinase (DDK), is also required for S-
phase entry. DDK consists of a catalytic subunit Cdc7 and a regulatory subunit Dbf4 that 
confers substrate specificity (10). Cdc7 protein levels are constant throughout the cell 
cycle. However, kinase activity is periodic, peaking at the G1/S boundary.  Activation of 
the Cdc7 kinase requires interaction with the regulatory subunit Dbf4, which is expressed 
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in late G1-phase and turned over rapidly allowing for a short burst of Cdc7 activity at the 
beginning of S-phase. Thus, Cdc7 kinase activity appears to be the last regulatory step 
before the initiation of DNA replication (9). 
 
1.2.3 Initiation of DNA replication 
The initiation of replication, or origin firing, occurs as cells enter S-phase (13).  
Activation of the pre-RC by protein kinases results in Cdc45 binding to the Mcm2-7 
complex (14), which appears to be the most critical event in origin firing. Both Cdc45 
and the Mcms are required for initiation and elongation steps of DNA replication. Cdc45 
is less abundant than the Mcm proteins and is therefore rate limiting for replication. The 
ratio of the Mcm2-7 complex to ORC is 40:1 while the ratio of Cdc45 to Orc is 2:1 (10). 
Both Cdc7/Dbf4 and Clb-Cdc28 activity is required for Cdc45 loading. In addition, this 
step may be mediated by Dpb11, which is part of a CDK-regulated complex and is 
required for Cdc45 loading. One model suggests that DDK phosphorylation of Mcms 
causes a change in the complex to allow a limited amount of Cdc45 to bind to the Mcms 
at the origin (10). Once Cdc45 is bound, the replication origins unwind to allow binding 
of the single strand DNA binding protein Rpa, then DNA polymerase alpha (α) and 
epsilon (ε) are recruited (10,14). Origin unwinding depends on Cdc45 forming a complex 
with Sld3. SLD3 was isolated in S. cerevisiae as a gene interacting with DPB11. Dpb11, 
when bound by Sld2/Drc1 associates with DNA polymerase ε at the replication origin 
(14). There are at least two independent functions of Dpb11. It is required for the 
initiation of DNA replication and is important for checkpoint responses to unreplicated or 
damaged DNA. 
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There is some evidence that the Mcm2-7 complex has helicase activity and all six 
Mcms are required for DNA unwinding. Moreover, Cdc45 may be the essential cofactor 
that converts the Mcm complex to an active DNA helicase. The GINS complex also 
appears to be essential for DNA unwinding. GINS is a ring-shaped, four protein complex 
that is highly conserved from archaea to eukaryotes (10), which is required for the 
loading of both Cdc45 and Dpb11 onto origin DNA and then becomes associated with 
moving replication forks (15). 
Another protein, Mcm10, also participates in recruiting Cdc45 to origin DNA and 
regulates DNA polymerase α stability (10,16). After the replication origins have been 
activated, the Mcm2-7 complex and Cdc45 move with the assembled replication enzymes 
at the forks to complete DNA replication. After initiation, the movement of the Mcm2-7 
complex away from the origin converts the origin to an unlicensed state thus preventing 
re-initiation (14).  
After DNA unwinding is initiated, the DNA synthesis machinery, the replisome, 
is assembled and DNA replication begins. DNA synthesis begins with DNA polymerase 
α associating with primase to initiate a short RNA primer, which is then extended by 
DNA polymerases. Next, DNA polymerase α is replaced with the more processive 
polymerases, delta (Δ) or epsilon (ε). At the same time, PCNA, the “sliding clamp” 
processivity factor is loaded.  PCNA loading is dependent on a clamp-loading complex 
replication factor C (Rfc), which promotes the polymerase switch. One strand of DNA is 
synthesized as the leading strand the other as the lagging strand. Leading strand synthesis 
is very efficient, highly processive and follows closely behind the helicase. Lagging 
strand synthesis requires multiple cycles of priming and extension as the underlying DNA 
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is exposed and synthesis occurs in the direction away from the helicase. Lagging strand 
synthesis results in Okazaki fragments that must be processed by nucleases and DNA 
ligase to create a single DNA chain. To protect the underlying DNA and ensure 
completion of DNA synthesis, leading and lagging strand synthesis remains coupled 
throughout S-phase (10). 
 
1.2.4 Cdc45 
To better understand the process of cell division, a cold sensitive (cs) genetic 
screen in S. cerevisiae was used to identify more than 40 essential genes whose products 
were needed to carry out cell division. One mutant, cdc45-1 (for cell division cycle 45), 
was shown to arrest at medial nuclear division, with a single large bud and the nucleus in 
the neck between the mother and daughter (17).   
Several groups simultaneously reported the isolation of a gene encoding the 
Cdc45 protein. Zou and colleagues reported the predicted protein sequence of S. 
cerevisiae Cdc45 as a 74.2 kilo Dalton (kDa) acidic protein with a bipartite nuclear 
localization sequence. The cold sensitive mutant, cdc45-1, is defective in initiating DNA 
replication and has inefficient origin firing at the non-permissive temperature suggesting 
Cdc45 functions at replication origins and affects the frequency of origin firing. cdc45-1 
is synthetically lethal with orc2-1, mcm2-1 and mcm3-1 confirming the interaction of 
Cdc45 with Mcm and ORC and further suggesting that all three act together in the 
initiation of DNA replication (18). 
At the same time, Hopwood and Dalton reported the isolation of Cdc45 as a 650 
amino acid polypeptide that is essential for the initiation of chromosomal DNA 
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replication in S. cerevisiae, yet shows no obvious homology with the Mcm family of 
proteins. They used a conditional cdc45 null mutant strain where the Cdc45 protein can 
be rapidly degraded at 37° due to a signal peptide that was fused to the N-terminus 
creating a temperature-sensitive degron signal. At 37°C this strain is not viable. The cells 
arrest uniformly at the G1/S boundary with a 1N DNA content suggesting Cdc45 is 
required for an early step in DNA replication. This phenotype is similar to the cold 
sensitive cdc45-1 mutant that was previously characterized and the same as the 
phenotype associated with many Mcm mutants. In immunoprecipitation studies, 
Hopwood and Dalton showed that Cdc45 forms a complex with Mcm5 in the Mcm2-7 
multi-protein complex and is localized in the nucleus throughout the cell cycle. In 
contrast, the Mcm proteins shuttle in and out of the nucleus in a cell cycle dependent 
manner.  Hopwood and Dalton mapped the canonical bipartite nuclear localization signal 
(NLS) to residues 209-228 as mutations of these residues abolish Cdc45 nuclear import 
(19). A bipartite NLS consists of two essential interdependent domains of basic amino 
acids separated by a 10 amino acid spacer (20). 
By complementation of the cold sensitive cdc45-1 mutant, Hardy mapped CDC45 
to an open reading frame on Chromosome XII. FASTA/BLAST analysis suggested 
Cdc45 was similar toTsd2 from Ustilago maydis, which also has a role in DNA 
replication (19,21). The amino acid sequences of Cdc45 and Tsd2 are 30% identical and 
50% similar. Hardy also reported that CDC45 is G1/S cell cycle regulated at the mRNA 
level.  The MluI cell cycle box (MCB) is the upstream regulatory sequence that drives 
G1/S specific gene expression and enzymes involved in DNA synthesis are 
transcriptionally regulated by MCB elements in their upstream non-translated sequences. 
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CDC45 contains two MluI sites 145 base pairs and 175 base pairs upstream of the start 
codon. An analysis of CDC45 RNA levels showed transcription peaks in early G1 and is 
diminished as cells enter S-phase suggesting regulation is in a G1/S specific manner. This 
is consistent with the pattern of other MCB regulated genes such as PCNA (21). 
However, the Cdc45 protein appears to be long-lived and is constant throughout the cell 
cycle. 
Another mutant allele of Cdc45 is cdc45-10. This temperature sensitive allele was 
isolated in the Bjornsti lab using a S. cerevisiae genetic screen to identify conditional 
mutants with enhanced sensitivity to DNA Top1-mediated DNA damage. Since yeast 
sensitivity to CPT is modulated by the pleiotropic drug resistance network, the self-
poisoning Top1T722A mutant was used as a source of DNA damage (5). Substituting Ala 
for Thr722 increases the stability of the covalent Top1-DNA intermediate, mimicing the 
cytotoxic action of CPT. The cdc45-10 mutant encodes a Gly to Arg substitution at 
amino acid 510 near the C-terminus of the protein (22). The mutant cells exhibit 
enhanced sensitivity to CPT, UV and a replication inhibitor hydroxyurea (HU), at the 
non-permissive temperature, 36°C (5). cdc45-10 cells also transiently accumulate in early 
S-phase when shifted to 36°C due to defective Okazaki fragment maturation. These cells 
exhibit a slow growth phenotype at 36° when a component of the DNA damage 
checkpoint, Rad9, is deleted suggesting that the damage occurring in these cells is 
recognized by this pathway (22). 
 As described above, Cdc45 is a member of a growing number of gene products 
that are required for cells to initiate DNA replication. Cdc45 associates with chromatin at 
the G1/S transition after “START” as cells move to S-phase and this is crucial for 
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committing the cells to initiation of DNA replication (23,24). Cdc45 is also required for 
Polα loading onto chromatin and associates with Mcm2, Rpa and Polε a part of the 
elongation machinery. It is suggested that Cdc45 and Rpa may continually stimulate 
Mcm helicase activity during replication elongation (25). Sld3 is another protein that is 
required for Cdc45 binding at origins. Sld3 and Cdc45 must form a complex in order for 
either protein to associate with origin DNA. Studies have shown that the Sld3-Cdc45 
complex associates with origins through the interaction of Cdc45 and the Mcm2-7 
complex.  Once Sld3-Cdc45 is bound, origin DNA unwinds and is bound by replication 
factor A (RF-A), the single-strand DNA binding protein (15). The function of Sld3 is 
limited to events prior to initiation; it is not required for the completion of replication 
once early origins have fired and does not move with replication forks. In contrast, the 
GINS complex is not needed for the initial recruitment of Cdc45 but is required for the 
stable engagement of Cdc45 with the previously bound replication machinery, and then 
becomes stably associated with the Mcm2-7 complex during replication elongation (26). 
Due to its ring-like shape, GINS may act as a clamp for replication proteins such as Pol ε 
that function during the elongation steps of replication (15). In vitro GINS forms a 1:1 
complex with Polε and greatly stimulates its catalytic activity. Polε is also more 
processive and dissociates from replicated DNA more easily when GINS is present. The 
GINS complex has also been show to promote the interaction between Sld2-Dpb11-and 
Polε (27). Dpb11 is required for DNA polymerases to associate with origins. Sld2 and 
Dpb11 form a complex when Sld2 is phosphorylated by S phase Cdk activity and this 
complex is essential for DNA replication. Dpb11 is required for GINS association with 
origin DNA. The interaction between GINS and Dpb11 must be limited to assembly at 
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origin DNA because Dpb11 dissociates from replication forks after its function is 
complete and therefore does not move with replication forks during elongation (15).  
dpb11-10 is a temperature sensitive allele that was isolated from the same genetic screen 
as cdc45-10. dpb11-10 cells exhibit a similar phenotype to cdc45-10 cells: they are 
hypersensitive to CPT, UV and HU at 36°C and they transiently accumulate in early S-
phase at 36°C due to a defect in Okazaki fragment maturation (22). A double mutant 
strain, containing both the cdc45-10 and dpb11-10 mutations, is temperature sensitive for 
growth at 36°C in the absence of DNA damage, indicating a synthetic interaction 
between Cdc45 and Dpb11 (22).  
CDC45L is the human homolog of S. cerevisiae CDC45. It is 30 kilobases long 
with 15 introns and 16 exons that encode a protein of 566 amino acids with a molecular 
mass of 64 kDa. Cdc45L is 27.6% identical and 52% similar to S. cerevisiae Cdc45 and 
26.8% identical and 49.5% similar to Ustilago maydis Tsd2p. Like the fungal proteins, 
Cdc45L also contains a bipartite nuclear localization signal. Cdc45L mRNA levels 
increase during the G1/S transition, but protein levels remain constant throughout the cell 
cycle, which is typical of proteins involved in the initiation of DNA replication. The 
Cdc45L gene is located on chromosome 22q11.2 and one copy of the gene is frequently 
deleted in DiGeorge syndrome (DGS) patients. DGS is marked by parathyroid 
hypoplasia, thymic aplasia, or hypoplasia and cardiac abnormalities. Since DGS is a 
developmental anomaly of the derivatives of the third and fourth pharyngeal pouches in 
the embryo and Cdc45L is the first gene identified in the DGS critical region that is 
required for cell division, deleting one copy may impair cell division during embryo 
development leading to the abnormalities seen in DGS patients (28). 
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The goals of this dissertation project were to understand how alterations in Cdc45 
function affects cell sensitivity to DNA topoisomerase I poisons and to better understand 
the function of Cdc45 as a component of replication complexes. Both of these goals were 
achieved by characterizing the defects in the cdc45-10 mutant cells. First, a genetic 
screen was developed to isolate dosage suppressors of cdc45-10 that allow cdc45-10 cells 
to survive in the presence of DNA Top1 poisons. The essential function of Cdc45 in 
initiation and elongation steps of DNA replication was also assayed by isolating 
replication intermediates, then using two-dimensional gel electrophoresis to compare the 
initiation of replication and the progression of replication forks in the mutant and wild-
type cells. An antibody was also raised against S. cerevisiae Cdc45, to assess alterations 
in protein levels and modifications that dictate differences between the Cdc45 mutant and 
wild-type protein function.  
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CHAPTER 2: GENETIC ANALYSIS OF cdc45-10 
 
2.1 INTRODUCTION 
Eukaryotic DNA topoisomerase I (Top1) plays a critical role in DNA replication, 
recombination and transcription by catalyzing the relaxation of supercoiled DNA through 
a mechanism of transient DNA strand cleavage and religation (1,2). Top1 is a monomeric 
enzyme that forms a protein clamp around duplex DNA. The active site tyrosine (Tyr727 
in yeast Top1) acts as a nucleophile to cleave the phosphodiester backbone of a single 
DNA strand, forming a covalent 3’ phospho-tyrosyl linkage with the DNA. Within this 
covalent Top1-DNA complex, the rotation of the 5’ DNA end about the nonscissile 
strand relaxes the overwinding or underwinding of the DNA strands (positive or negative 
supercoils, respectively). The 5’OH of the cleaved DNA strand acts as a nucleophile in a 
second transesterification reaction to resolve the Top1-DNA intermediate and religate the 
DNA (1,2). 
Top1 is the sole cellular target of the anticancer agent camptothecin (CPT). CPT 
targets Top1 by reversibly binding the covalent enzyme-DNA intermediate, which 
prevents religation of the cleaved DNA. The stabilized drug-enzyme-DNA intermediates 
are formed in all stages of the cell cycle; however, the cytotoxic activity of CPT is S-
phase dependent. Two mechanisms have been advanced to explain the replication-
dependent toxicity of camptothecins. First, biochemical and genetic data suggest 
advancing replication forks collide with the stabilized CPT-Top1-DNA complexes to 
induce irreversible DNA lesions that trigger checkpoint activation and cell death (6). 
However, a recent study of camptothecin analog poisoning of human Top1 in a single 
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molecule setting and in yeast cells suggests a distinct mechanism (8), whereby drug 
binding of Top1-DNA complexes induces the accumulation of positive supercoils in front 
of the moving replication fork. Such local domains of high superhelical density would 
block fork progression, resulting in fork collapse and lethal DNA lesions that induce cell 
death (8). However, despite extensive study, little is known of the molecular interactions 
that convert the ternary Top1-DNA-CPT complexes into the DNA lesions that trigger 
checkpoint activation or the downstream pathways required for the resolution and repair 
of these lesions. 
The budding yeast S. cerevisiae has proved an invaluable model for studies of 
processes such as DNA replication and the mechanism of action of cancer therapeutics 
(29). This genetically tractable microorganism has a genome of relatively low 
complexity, exhibits high rates of homologous recombination and can be readily 
transformed with mitotically stable plasmids. Mating of haploid strains of opposite 
mating type to generate diploid cells, coupled with a sporulation program that allows the 
recovery of all four meiotic products in a single ascus, underlies the facile genetics 
necessary to elucidate complex cellular processes (29). Indeed, most basic cellular 
processes and the cell cycle machinery are highly conserved from yeast to human, as are 
the mechanisms of cell sensitivity and resistance to CPT. Yeast cells deleted for TOP1 
(top1Δ) are viable due to the presence of other activities, such as that of DNA 
topoisomerase II, which maintain cell viability. However, top1∆ strains are resistant to 
CPT. Drug sensitivity can be restored by the expression of plasmid encoded yeast or 
human Top1 (6). These studies establish Top1 as the cellular target of CPT, which 
converts Top1 into a cellular poison. 
21 
Alterations in the DNA cleavage-religation equilibrium of Top1, induced either 
by drug binding or mutation of residues within the catalytic pocket of the enzyme, poison 
Top1 by enhancing covalent complex stability. For example, mutation of Thr722 to Ala 
in Top1T722A induces a decrease in the rate of DNA religation and acts as a CPT 
mimetic. DNA repair and checkpoint proficient yeast cells can tolerate low-level 
expression of this self-poisoning top1T722A mutant (5). Thus, this mutant allele provides a 
valuable tool for identifying gene products and pathways that mediate cellular responses 
to CPT, while avoiding the complications of drug uptake and efflux. As diagrammed in 
Fig. 2.1, a genetic screen was designed to isolate conditional (temperature sensitive or ts) 
mutants with enhanced sensitivity to Top1T722A, thereby identifying gene products that 
act normally to protect cells against Top1-mediated damage. 
In this screen, top1Δ cells, transformed with a plasmid that constitutively 
expresses low levels of Top1T722A, were mutagenized with ethyl methanesulfonate 
(EMS) and grown at 26°C. Following replica plating, colonies that were viable at 26°C, 
but inviable at 36°C, were selected as potential tah (Top1T722A hypersensitive) mutants. 
At 36°C, tah mutants were unable to survive damage induced by Top1T722A due to the 
loss or decrease of TAH gene product function. To ensure that the phenotype of the tah 
mutants was linked to top1T722A expression, the cells were first cured of the URA3 
marked vector by successive replica plating on media containing 5-fluoroorotic acid (5-
FOA), then re-screened for growth at 36˚C. In the absence of Top1T722A, the top1∆, tah 
mutants were viable at 36°C and cell growth was unaffected by the expression of Top1. 
Extensive backcrossing of individual tah mutants with an isogenic wild-type strain 
identified ten recessive mutants that defined nine complementation groups. The  
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Fig. 2.1 Screen for Top1T722A hypersensitive (tah) mutants 
Yeast cells deleted for TOP1 were transformed with a vector expressing low levels of 
Top1T722A. The transformants were EMS mutagenized and plated at 26°C. Those 
transformants that grew at 26° but failed to grow when plated at 36°C were isolated as 
tah mutants. To ensure the temperature sensitivity was linked to Top1T722A, cells were 
cured of the URA3 based plasmid using 5-FOA and re-screened for temperature sensitive 
growth. 
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corresponding wild-type TAH alleles were cloned by complementation using a low copy 
vector-based yeast genomic DNA library. As summarized in Fig. 2.2, at the non-
permissive temperature, the tah mutants were also hypersensitive to CPT, when the cells 
expressed wild-type Top1. The mutants also exhibited enhanced sensitivity to the 
ribonucleotide reductase inhibitor hydroxyurea (HU), which further suggested defects in 
DNA replication. The tah mutants exhibited varying levels of sensitivity to other DNA 
damaging agents, such as the alkylating agent methyl methanesulfonate (MMS) and UV 
light. The majority of TAH genes encode essential gene products, suggesting that the tah 
mutants were hypomorphic. They also function in a surprising variety of cellular 
processes. UBC9 encodes the sole SUMO E2 conjugating enzyme in yeast. DOA4 
encodes a C-terminal ubiquitin hydrolase that functions to maintain ubiquitin 
homeostasis. TAF47 (re-named TAF3) encodes a TATA binding protein that regulates 
global transcription from the RNA polymerase II promoter. SLA1 encodes a cytoskeletal 
binding protein required for the assembly of the cortical actin cytoskeleton. SLA2 
encodes a transmembrane actin-binding protein involved in membrane cytoskeleton 
assembly and cell polarization. 
As diagrammed in Fig. 2.3, three of the TAH genes are essential for DNA 
replication.  CDC45 encodes a DNA replication initiation factor that is essential for the 
initiation and elongation steps of DNA replication. DPB11 encodes a subunit of the DNA 
polymerase II epsilon (ε) complex that is essential for the loading of DNA polymerases to 
initiate DNA synthesis and is required for the S-phase checkpoint. TAH11 encodes a 
DNA replication licensing factor required for pre-replicative complex formation (5). As 
shown in Fig. 2.4, the tah mutant, cdc45-10, harbors a single mutation where Arg  
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Fig. 2.2 TAH genes 
TAH genes encoding essential gene products are depicted in bold print. TAH gene 
products function in different cellular processes: DPB11, CDC45 and TAH11 encode 
proteins that function in DNA replication, UBC9 encodes the sole E2 SUMO conjugating 
enzyme, SLA1 and SLA2 encode gene products involved in cortical actin organization, 
TAF47 (re-named TAF3) encodes a transcription factor component and DOA4 encodes a 
ubiquitin hydrolase. The tah mutants are all hypersensitive to CPT and HU at 36°C and 
some are also hypersensitive to MMA and UV light. 
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Fig. 2.3 TAH gene function in DNA replication 
Three of the TAH genes encode gene products that are essential for DNA replication. 
Tah11 functions in pre-replicative complex formation, Cdc45 is required for the initiation 
and elongation steps of replication and Dpb11 functions in polymerase switching and 
checkpoint activation. 
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Fig. 2.4 cdc45-10 
The tah mutant cdc45-10 encodes a single missense mutation (G510R). The cells are 
viable when TOP1 is present or deleted (top1Δ), however, cell viability is lost at 36˚C 
when the cells express low constitutive levels of the CPT mimetic, Top1T722A. 
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substituted for Gly510. With the exception of a bipartite nuclear localization signal, the 
amino acid sequence of Cdc45 does not predict similarities with any known domains. 
cdc45-10 cells are viable when either TOP1 is deleted or is expressed, however, the cells 
are hypersensitive to Top1T722A expression at 36°C. cdc45-10 cells transiently 
accumulate in early S-phase when shifted to 36°C due to a defect in Okazaki fragment 
maturation.  They also exhibit a slow growth phenotype when RAD9 is deleted 
suggesting that damage accumulates and is sensed by the Rad9 DNA damage checkpoint. 
Double mutant strains were constructed by combining the different tah alleles. The 
combination of cdc45-10 with dpb11-10 resulted in a double mutant strain that was 
inviable at 36°C in the absence of exogenous DNA damage. This synthetic lethal 
interaction suggests that Cdc45 and Dpb11 share a common essential function.  Because 
Cdc45 is required for polymerase α loading and Dpb11 is a subunit of the DNA pol II ε 
complex, which is required for DNA polymerase loading, the shared function of Cdc45 
and Dpb11 could be switching between the pol α primase to the more processive 
polymerases ε and δ. 
Despite extensive study, the exact function of Cdc45 during the initiation and 
elongation steps of DNA replication has yet to be defined. Our findings suggest that 
Cdc45 functions normally to protect cells against Top1 induced DNA damage. However, 
further characterization of the replication defects in cdc45-10 cells would provide 
insights into the molecular interactions required for cellular resistance to Top1-induced 
DNA damage. In this study, we report that cdc45-10 (cdc45G510R) is hypomorphic for 
resistance to Top1T722A-induced DNA damage; however, this was not due to alterations 
in Cdc45G510R protein levels. In contrast, increased expression of this mutant allele failed 
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to suppress the synthetic lethality of cdc45-10,dpb11-10 cells, suggesting distinct effects 
of the G510R substitution on Cdc45 function in response to Top1 poisons and it’s 
interactions with Dpb11. These findings were further supported by the results of a yeast 
genetic screen for dosage suppressors, which identified the SUMO E3 ligase, Siz1, as a 
partial dosage suppressor of cdc45-10 cell sensitivity to Top1T722A, but not cdc45-
10,dpb11-10 synthetic lethality. Indeed, a cdc45 SUMO consensus site mutant also 
exhibited a synthetic lethal interaction with dpb11-10, suggesting the functional 
interaction of these replication proteins is facilitated by SUMO modification. 
 
2.2 EXPERIMENTAL PROCEDURES 
 
2.2.1 Chemicals, plasmids and yeast strains 
Camptothecin, purchased from Sigma, was dissolved in dimethyl sulfoxide 
(DMSO) and 4 mg/ml stock solutions were stored at -20˚C. Hydroxyurea (HU) and 5-
fluoroorotic acid (5-FOA) were obtained from U.S. Biological.  20T Zymolyase was 
purchased from Seikagaku Corp. 
Plasmids and yeast strains used in these studies are listed in Table 2.1 and 2.2, 
respectively. Plasmids were amplified in Escherichia coli TOP10F’ cells (Invitrogen) and 
purified using a kit from Qiagen. All mutations were confirmed by DNA sequencing. The 
isogenic yeast strains were derived from FY250 (30). Where indicated, gene disruptions 
were accomplished by PCR-based homologous recombination (31) and confirmed by 
PCR of genomic DNA using primers that flanked the site of integration within the 
genomic DNA. Primer sequences are available upon request. 
29 
Table 2.1 Plasmids 
Plasmids Characteristics Reference 
YCpSctop1T722A•U A 2.9-kb BamH1-XbaI fragment excised from 
YCpGAL1top1T722A was ligated into YCpSc•U 
(32) 
YCpSctop1T722A•H CEN6/ARSH4; a 3.5-kb XhoI-NotI fragment of 
top1T722A was excised from YCpSctop1T722A•U, 
and ligated into the same site in pRS413 
(32) 
YEp24pL Modified YEp24 vector with multiple cloning site 
of pBluescript 
(33) 
YEp•FY250 genomic 
DNA library 
6-10kb genomic fragments were ligated into 
partially Sau3A-digested DNA into 
dephosphorylated BamHI ends of YEp24pl  
(34) 
YEp•HCS81 Genomic fragment from YEp•FY250 genomic 
DNA library inserted into the BamHI site of 
YEp24pL 
This work 
YEp•HCS86 Genomic fragment from YEp•FY250 genomic 
DNA library inserted into the BamHI site of 
YEp24pL 
This work 
YCpCDC45 CEN6/ARSH4;URA3; genomic fragment of 
CDC45 cloned into pRS416. 
(22) 
YEpCDC45 2 µm; URA3; Not1-Sal1 fragment of YCpCDC45 
cloned into YEp24pL.  
(22) 
YCpcdc45-10 CEN6/ARSH4; URA3; HindIII-SpeI fragment of 
the cdc45G510R mutant from chromosome XII 
ligated into pRS416.  
(22) 
YEpcdc45-10 2 µm; URA3; HindIII-SpeI fragment of 
YCpcdc45-10 ligated into YEp24pL 
This work 
pAG60 TEF-promoter/terminator; C. albicans URA3 
cassette 
(31) 
pCLcdc45-10 PvuII-HindIII fragment from YEpcdc45-10 
cloned into pAG60. 
This work 
pRS415 CEN6/ARSH4; LEU2 (35) 
YCpCDC45•L EagI-SalI fragment of CDC45 was excised from 
YCpCDC45 and ligated into pRS415 
This work 
YCpcdc45-10•L NotI-HindIII fragment of pCLcdc45-10 was 
excised and cloned into pRS415 
This work 
pRS413 CEN6/ARSH4; HIS3 This work 
pRS416 CEN6/ARSH4; URA3 (34) 
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Table 2.1 (continued) 
Plasmids Characteristics Reference 
pCLcdc45SUMO,G510R Lys385 of pCLcdc45-10 was mutated to Arg using 
oligonucleotide-directed mutagenesis 
This work 
YCpCDC45-HA•L CEN6/ARSH4; LEU2; CDC45-HA amplified 
from CLY6 and cloned into pRS415 using EagI 
and SalI 
This work 
YCpcdc45-10-HA•L CEN6/ARSH4; LEU2; EagI-PstI fragment of 
YCpCDC45•L excised and ligated into 
YCpCDC45-HA to create G510R mutation 
This work 
pFA6a-3HA-His3MX6 Sequence encoding 3HA with S. cerevisiae 
ADH1 terminator and the His3MX6 module 
including the S. pombe his5+ gene 
(36) 
YCpCDC45SUMO•L BstZ71I-NcoI fragment of pCLcdc45SUMO,G510R 
was cloned into YCpCDC45•L 
This work 
YCpcdc45SUMO,G510R•L BstZ71I-NcoI fragment of pCLcdc45SUMO,G510R 
was cloned into YCpcdc45G510R•L 
This work 
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Table 2.2 Yeast strains 
Strain Genotype Reference 
EKY2 MATa, ura3-52, his3Δ200, leu2Δ1, trp1Δ63, top1Δ::HIS3 (22) 
EKY3 MATα, ura3-52, his3Δ200, leu2Δ1, trp1Δ63, top1Δ::TRP1 (22) 
RRY72-7 EKY3, cdc45-10 This work 
RRY72-2 EKY2, cdc45-10 This work 
RRY71-7 EKY3, dpb11-10 (22) 
RRY81-1 EKY3, tah11-10 This work 
RRY82 EKY3, ubc9-10 (32) 
MSY18-6 EKY3, cdc45-10, dpb11-10 This work 
PTY35 MATα, ura3-52, his3Δ200, leu2Δ1, trp1Δ63, 
cdc45Δ::his5+, YCpCDC45 
This work 
CLY6 MATα, ura3-52, his3Δ200, leu2Δ1, trp1Δ63,CDC45 C-
terminally tagged with HA using pFA6a-3HA-His3MX6 
This work 
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2.2.2 Yeast transformations 
Lithium acetate treated yeast cells, transformed with URA3, LEU2, TRP1 or 
HIS3-marked plasmids were selected on synthetic complete media lacking uracil (SC-
ura), leucine (SC-leu), histidine (SC-his) or tryptophan (SC-trp), and supplemented with 
2% (w/v) dextrose. 
 
2.2.3 Cell viability assays 
To assay cell sensitivity to Top1T722A, exponential cultures of cells transformed 
with the indicated YCptop1T722A vector, were grown in selective media at 26°C, 
adjusted to an O.D. = 0.3. Serial ten fold dilutions were then spotted in 5 µl aliquots onto 
selective plates supplemented with dextrose. To assay cell sensitivity to HU, plates were 
supplemented with 5 mg/ml HU. For CPT sensitivity, the agar plates were supplemented 
with 25 mM HEPES (pH 7.2) and 0 or 5 μg/ml CPT in a final 0.125% DMSO. In all 
cases, cell viability was assessed following incubation at 26˚C or 36˚C. 
 
2.2.4 Isolation of dosage suppressors 
cdc45-10 (RRY72) cells were co-transformed with YCpSctop1T722A•H and the 
YEp-FY250 yeast genomic DNA library and selected on SC-ura,-his plates at 36˚C. To 
ensure that cell viability at 36°C was due to the presence of the genomic DNA fragment 
contained in the YEp plasmid, the cells were cured of the URA3-marked YEp plasmid by 
successive replica plating of the transformants on SC-his plates supplemented with 5-
FOA. The resulting colonies were then replica plated onto SC-his plates and incubated at 
36°C. For those colonies that were inviable at 36˚C, the YEp vector was then recovered 
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from the original transformants for further characterization. Individual transformants, 
grown in SC-ura at 26°C, were collected by centrifugation, washed with dH2O, 
resuspended in 1M sorbitol, 20mMEDTA and treated with a freshly prepared solution of 
20T zymolyase in 1M sorbitol at 37°C for 30 minutes. The spheroplasts were then 
pelleted, resuspended in buffer P1 from the Qiagen miniprep kit and the plasmid DNA 
was purified as per the manufacturer’s instructions. The purified plasmids were 
subsequently amplified in E. coli TOP10F’ cells, and the DNA from individual 
transformants were digested with XbaI and EcoRI to determine the size of the yeast 
genomic DNA inserts. The restriction enzymes were chosen based on the restriction maps 
of YCpCDC45, YCpSctop1T722A and YEp24pL.  Digesting YCpCDC45 with XbaI and 
EcoR1 yields a 1.4 kilobase (kb) fragment of CDC45 that was used as a control to 
determine if any inserts in the plasmids were CDC45, whereas digests of 
YCpSctop1T722A or YEp24pL served to distinguish Top1T722A and vector fragments 
from vectors containing genomic DNA inserts. The restriction digests were resolved in 
agarose gels and visualized by ethidium bromide staining using a BioRad Gel Doc 
System.  The high copy suppressor digests were compared to that of the vector controls to 
determine the insert size.  The recovered plasmids were verified by transformation with 
YCpScTop1T722A into cdc45-10 cells. Individual colonies were picked and grown in 
selective media at 26°C.  Cell viability assays were used to access cell viability at 26°C 
and 36°C. The high copy suppressor inserts were sequenced using T3 and T7 primers.  
The DNA sequences obtained were used to query the Saccharomyces genome database 
(SGD) and to identify the genomic DNA inserts. 
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As each insert contained multiple reading frames, further subcloning determined 
which open reading frame was responsible for the dosage suppression. YEp24-HCS86 
was digested with EagI to excise 1.2 kb of the 5.5 kb insert, leaving the entire SIZ1 ORF 
and 179 base pairs of the 644 base pair ADE8 gene. YEp24-HCS81 was digested with 
SalI to excise the complete NDI1 gene including 140 base pairs upstream of the start 
codon. This fragment was ligated into YEp24pl and the remainder of the digested 
plasmid was religated. Each plasmid was co-transformed with YCpTop1T722A into 
cdc45-10 cells and viability was accessed at 26°C and 36°C. 
 
2.2.5 SUMO site mutations  
Substitution of Arg for Lys385, in the consensus sumoylation site IK385RE of 
Cdc45G510R, was accomplished by oligonucleotide-directed mutagenesis of pCLcdc45-
10 with the Quick Change Site-Directed Mutagenesis Kit (Stratagene) to generate 
pCLcdc45SUMO,G510R , using the primer pairs  
5’CATGGATCATTCTATTAGGAGAGAACTTGGG 3’ and  5’ 
CCCAAGTTCTCTCCTAATAGAATGATCCATG 3’. The DNA fragment spanning the 
SUMO site mutant was then excised with BSTZ71I and Nco1 and ligated into the 
corresponding sites in YCpCDC45•L and YCpcdc45-10•L, to generate 
YCpCDC45SUMO•L and YCpcdc45SUMO, G510R•L, respectively. 
 
2.2.6 Plasmid shuffle 
To create the cdc45Δ plasmid shuffle strain (PTY35), wild-type FY250 cells were 
transformed with YCpCDC45 and the genomic copy of CDC45 was replaced with the 
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his5+ gene via PCR based homologous recombination (36). The primers used 5’ 
TAGAGAGAAGGCACATAATAACAAGAATATACTCTCGCACCGGATCCCCGGGTTA
ATTAA 3’ and 
5’AATTTTGATTATAACAATCCACTCAAGGTCAGCTTCTCCAGGAATTCGAGCTCGT
TTAAAC 3’ contained 40 bases that were complementary to sequences flanking the 5’ 
and 3’ ends of CDC45 (in italics), respectively, while the remaining sequences are 
complementary to plasmid sequences flanking the his5+ gene. YCpCdc45•L, 
YCpCdc45SUMO•L, YCpcdc45-10•L and YCpcdcSUMO, G510R•L vectors were transformed 
into the cdc45Δ strain and individual transformants were cured of the URA3-based vector 
by successive replica plating on 5-FOA.  Viable cells, containing only the LEU2 vectors, 
were selected for further characterization. 
 
2.3 RESULTS 
 
2.3.1 cdc45-10 is a hypomorphic mutant 
The tah screen for conditional mutants exhibiting enhanced cell sensitivity to 
Top1 poisons (described in Fig. 2.1) generated temperature sensitive mutations in several 
essential genes including CDC45, DPB11, TAH11 and UBC9. In the case of the ubc9-10 
mutant, we reported that the mutant protein was thermolabile at 36˚C, as steady state 
protein levels were reduced upon shift to the non-permissive temperature. The resultant 
decrease in global SUMO conjugation sufficed to maintain cell viability at 36˚C yet 
reduced cellular resistance to low levels of genotoxic stresses. These data indicated that 
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the ubc9-10 mutant was hypomorphic, such that the mutant phenotypes resulted from a 
decrease in Ubc9 function.  
To assess whether the phenotypes ascribed to the cdc45-10 mutant were also a 
consequence of a global decrease in Cdc45 function, we asked if increased copy number 
of the cdc45-10 mutant allele would restore cellular resistance to low levels of 
Top1T722A-induced DNA damage. To address this question, the entire coding region of 
the cdc45-10 allele and the 5’flanking sequences necessary for gene expression were 
cloned into a high copy 2µm-based vector. This vector was then co-transformed into 
cdc45-10 mutant cells with YCpSctop1T722A•H or vector control. As shown in Fig. 2.5, 
increased gene dosage of wild-type CDC45 or mutant cdc45-10 complemented the slow 
growth phenotype exhibited by cdc45-10 cells in the absence of DNA damage as well as 
the Top1T722A-induced cell lethality at 36˚C. These data suggest that cdc45-10 is 
hypomorphic for the defects necessary to protect cells from low levels of Top1-induced 
DNA damage.  
These data contrasted with the inability of YEpcdc45-10 to dosage suppress the 
synthetic lethal interactions of cdc45-10 with dpb11-10. As shown in Fig. 2.6, while 
increased dosage of wild-type CDC45 complemented the lethal phenotype of the cdc45-
10,dpb11-10 strain at 36˚C, YEpcdc45-10 failed to restore viability. These results raise 
two possibilities. First, there are distinct functions for Cdc45, one required to protect cells 
from low levels of S-phase DNA damage and another for the functional interaction with 
Dpb11. Alternatively, a lower threshold of Cdc45 function may be necessary for cellular 
resistance to Top1T722A in wild-type DPB11 cells, while higher levels of Cdc45 activity 
is needed to maintain cell viability when both Cdc45 and Dpb11 function is altered. 
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Fig. 2.5 Increased gene dosage of cdc45-10 restores cellular resistance to Top1T722A 
cdc45-10 cells were co-transformed with CDC45 or cdc45-10 vectors and Top1T722A. 
Expression of CDC45 (low copy or high copy) and high copy expression of cdc45-10 
restores cell viability to cdc45-10 cells in the presence of Top1T722A at 36˚C. 
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Fig. 2.6 Increased expression of cdc45-10 does not restore cell viability to the cdc45-
10, dpb11-10 double mutant strain 
The cdc45-10, dpb11-10 double mutant strain was transformed with vectors expressing 
low or high levels of CDC45 or a vector expressing high levels of cdc45-10. Low or high 
level expression of CDC45 (YCpCDC45 or YEpCDC45) was able to restore cell viability 
to the double mutant strain at 36˚C, however, increased expression of cdc45-10 
(YEpcdc45-10) was not able to restore cell viability at 36˚C. 
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2.3.2 Epitope tagging of Cdc45 and Cdc45G510R 
To address these questions, and the basis for the hypomorphic phenotype of 
cdc45-10 itself, we attempted to incorporate an epitope tag into the genomic copy of 
CDC45 and cdc45-10. This approach, of introducing a C-terminal HA tag into wild-type 
Cdc45, has been extensively used to characterize Cdc45 protein levels, interactions with 
other proteins and chromatin association (16,23-26,37,38). Thus, we anticipated this 
approach would be a relatively straightforward means of incorporating an epitope tag into 
Cdc45G510R. However, this was not the case. As summarized in Fig. 2.7, several 
approaches were taken. First, we attempted to introduce a hemagglutinin (HA) or Myc 
epitope tag at the C- terminus of Cdc45 and cdc45G510R by integrating sequences 
encoding these tags into the genome of haploid yeast strains using PCR-based 
homologous recombination. While this method was successful for CDC45 it was 
unsuccessful for cdc45G510R. In both cases, viable HIS+ cdc45-10 colonies were not 
recovered. Related attempts to recover an N-terminal HA-cdc45-10 strain also failed. As 
diagrammed in Fig. 2.7, these findings suggest that incorporating an epitope tag at either 
the N- or C-terminus of Cdc45G510R further impairs protein function such that the cells 
are no longer viable. 
To further investigate this possibility, CDC45-HA was amplified from genomic 
DNA and cloned into YCpCDC45-HA. A DNA fragment of cdc45G510R that contained 
the nucleotide sequence coding the G510R mutation was then ligated into YCpCDC45-HA 
to create YCpcdc45-10-HA. The tagged and untagged versions of these vectors were then 
shuffled into the cdc45Δ (TOP1 and top1∆) strains (as depicted in Fig. 2.8) and the 
ability of each cdc45 allele to maintain cell viability was assayed. As shown in Fig. 2.9, 
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Fig. 2.7 Epitope tagging of Cdc45 and cdc45-10 
A HA tag was incorporated at the C-terminus of CDC45 using PCR based homologous 
recombination. However, incorporating a HA or Myc tag at the C or N-terminus of 
cdc45-10 resulted in a protein that was not able to maintain cell viability. 
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Fig. 2.8 Plasmid shuffle 
Cells were transformed with a URA3 vector carrying wild-type CDC45. The genomic 
copy of CDC45 was deleted and replaced with HIS5+. The deleted strain was 
transformed with LEU2 vectors carrying the Cdc45 mutations to be assayed and cured of 
the URA3 vectors using 5-FOA. The cells carrying the LEU2 vectors were assayed for 
cell viability. 
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Fig. 2.9 Plasmid shuffle of untagged or C-terminally HA tagged CDC45 and cdc45-
10  
Vectors expressing C-terminally tagged or untagged CDC45 or cdc45-10 were shuffled 
into a cdc45Δ strain. CDC45, CDC45-HA and cdc45-10 were able to maintain cell 
viability while cdc45-10-HA was not able to maintain cell viability. 
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each of the untagged constructs and YCpCDC45-HA maintained cell viability, whereas 
cells containing YCpcdc45-10-HA as the sole source of Cdc45 were inviable. These 
results were independent of Top1. Moreover, they could not be ascribed to a decrease in 
protein function, as increased dosage of the cdc45-10-HA allele on a high copy YEp 
vector also failed to maintain cell viability (data not shown). In parallel, attempts to 
recover haploid cdc45-10-HA cells from heterozygous diploids following sporulation and 
tetrad dissection were also unsuccessful (data not shown). Taken together, these data 
demonstrate that the introduction of a C-terminal epitope tag into Cdc45G510R induces a 
null phenotype, consistent with a more severe defect in Cdc45 function. 
These results also questioned the effects of the C-terminal HA tag on wild-type 
Cdc45 function. The cdc45-10,dpb11-10 double mutant strain is inviable at 36°C in the 
absence of exogenous DNA damage. Thus, to determine if incorporating a C-terminal 
epitope alters wild-type Cdc45 protein function, YCpCDC45-HA and YCpcdc45-10-HA 
vectors were transformed into the cdc45-10,dpb11-10 double mutant strain and cell 
viability was assessed at 26°C, 30°C and 36°C. As shown in Fig. 2.10, YCpCDC45-HA 
and YCpcdc45-10-HA transformants exhibited a slow growth phenotype at 30°C, while 
neither vector restored cdc45-10,dpb11-10 cell viability at 36˚C. These findings suggest 
that incorporating an HA tag at the C-terminus of Cdc45 alters normal protein function, 
including that required to suppress the synthetic lethal interaction with dpb11-10. 
Although modifying the C-terminus of the protein induced interesting alterations in 
Cdc45 function, this strategy failed to provide a means of assessing Cdc45 protein levels 
in vivo. Therefore, we next attempted to generate peptide-based polyclonal antibodies. As 
shown in Fig. 2.11, several peptides were generated and used as antigens in rabbits. The 
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Fig. 2.10 The cdc45-10,dpb11-10 double mutant strain transformed with untagged 
and HA tagged Cdc45 vectors 
The cdc45-10,dpb11-10 strain was transformed with vectors expressing CDC45, CDC45-
HA, cdc45-10 and cdc45-10-HA and cell viability was assessed at 26˚C, 30˚C and 36˚C. 
YCpCDC45-HA and YCpcdc45-10-HA exhibit a slow growth phenotype at 30˚C, while 
neither vector can restore cell viability to cdc45-10,dpb11-10 at 36˚C. 
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Fig. 2.11 Peptides used to generate S. cerevisiae Cdc45 polyclonal antibodies 
Two antigens were used to immunize rabbits to produce a S. cerevisiae polyclonal Cdc45 
antibody. The peptide spanning amino acid region 444-457 failed to recognize Cdc45 
while the peptide spanning amino acid region 196-212 recognize the 74 kDa band 
corresponding to Cdc45. 
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resulting antibodies were purified on peptide-coupled resins as described (39). The 
antibody generated against the peptide spanning amino acids 444-457 failed to recognize 
Cdc45 in western blots of whole cell extracts. A second peptide, spanning amino acids 
196-212, was also used based on discussions with Bruce Stillman’s lab. This  
antibody recognized the 74 kilo dalton (kDa) band corresponding to Cdc45, which was 
confirmed in western blots of Cdc45-HA and in immunoprecipitations of Cdc45-HA 
proteins immunoblotted with our Cdc45 polyclonal antibody.  
 
2.3.3 Steady state levels of Cdc45G510R are unaltered at 36˚C 
As shown in Fig. 2.12, the steady state levels of Cdc45G510R protein obtained 
from crude extracts of asynchronous cells grown at the permissive (26˚C) or non-
permissive temperature (36˚C) mirrored those of wild-type Cdc45. Thus, unlike the 
dramatic decrease in Ubc9P123L protein levels induced upon shifting the tah mutant ubc9-
10 to the non-permissive temperature, the hypomorphic phenotype of cdc45-10 cells 
could not be attributed to the down regulation of a thermolabile protein. Although 
CDC45 gene expression is cell cycle regulated, Cdc45 protein levels have been reported 
to be constant throughout the cell cycle. Thus, the G510R mutation did not appear to alter 
mutant protein levels in exponentially growing cells, either in the presence or absence of 
Top1. 
 
2.3.4 High copy suppressors of cdc45-10 
As the increased gene dosage of cdc45-10 suppressed the hypersensitivity of these 
cells to Top1T722A, but not the synthetic lethality of cdc45-10,dpb11-10 cells, we posited 
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Fig. 2.12 Steady state protein levels of CDC45 and cdc45-10 asynchronous cultures 
Steady state protein levels of Cdc45 and cdc45-10 at 26˚C and 36˚C were visualized by 
western blots using the Cdc45 polyclonal antibody. In both, CDC45 and cdc45-10, there 
is an increase in protein levels at 36˚C compared to 26˚C. 
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that a yeast genetic screen for extragenic dosage suppressors of cdc45-10 would further 
define pathways specific for cellular resistance to Top1 poisons. As shown in Fig. 2.13, 
cdc45-10 cells were co-transformed with two vectors: a low copy ARS/CEN vector 
expressing Top1T722A from a weak constitutive promoter and a high copy (~50-200 
copies/cell) URA3-marked YEp vector containing random fragment of yeast genomic 
DNA. The transformants were selected for viability at the non-permissive temperature, 
36°C. To ensure that cell viability at 36°C was due to the presence of increased copies of 
a gene(s) in the YEp vector, the transformants were first patched onto SC-leu plates at 
26˚C, then successively replica plated onto SC-leu media supplemented with 5-FOA. 
Only cells that have lost the YEp-genomic DNA vector, yet retained the Top1T722A-
expressing vector would be viable under these conditions. These cells were then 
examined for Top1T722A-induced lethality at 36˚C. The YEp library plasmid was isolated 
from the original 26°C transformants that met these criteria and rescreened for gene 
dosage suppression of cdc45-10. Two high copy suppressors (HCS81 and HCS86) were 
isolated and identified by querying the Saccharomyces Genome Database (SGD) with 
DNA sequences obtained from the 5’ and 3’ ends of the inserts. As shown in Fig. 2.14, 
HCS81 contains a fragment of chromosome XIII, with two complete open reading frames 
(ORFs), two partial ORFs and an origin of replication, ARS 1303. Of the complete 
ORFs: NDI1 encodes a NADH-ubiquinone oxidoreductase and YML119W encodes a 
protein with unknown function. The two partial ORFs are GTR1 and NGL3. Based on 
annotated sequences obtained from the SGD, subsequent restriction digestion and 
subcloning of the individual ORFs in HCS81 failed to define any of the ORFs as a dosage 
suppressor of top1T722A-induced cdc45-10 cell lethality at 36˚C (data not shown). Rather, 
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Fig. 2.13 Isolation of dosage suppressors of cdc45-10 
cdc45-10 cells were co-transformed with Top1T722A and a high copy yeast genomic 
library, plated and grown at 36°C.  The transformants that were viable at 36°C were 
cured of the library plasmid using 5-FOA to ensure the viability 36°C was due to the 
presence of the library plasmid.  The plasmids were isolated, sequenced to identify the 
high copy suppressor fragment and re-screened for resistance to Top1T722A. 
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Fig. 2.14 Dosage suppressors of cdc45-10 complement other tah mutant cell 
sensitivity to Top1T722A 
HCS86 contains two complete ORFs and one partial ORF. When digested the fragment 
containing SIZ1 was responsible for the suppression of cdc45-10 and ubc9-10 in the 
presence of Top1T722A at 36°C. HCS81 contains two complete ORFs, two partial ORFs 
and the origin ARS1303. HCS81 restores cell viability to cdc45-10, dpb11-10 and tah11-
10 in the presence of Top1T722A at 36°C. 
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the presence of an additional origin of replication, ARS1303, in the YEp vector appeared 
to partially suppress the inability of cdc45-10 cells to grow on SC-leu,-ura (data not 
shown).  
Previous studies of conditional tah11 mutants suggested that a defect in origin 
licensing by Tah11 results in the preferential loss of ARS/CEN vectors, due to diminished 
plasmid replication resulting in plasmid instability. However, this defect in plasmid 
mitotic stability could be suppressed by the presence of multiple ARS elements on a 
single vector, thereby increasing the likelihood that at least one origin would fire per cell 
cycle. The identification of ARS1303 as a dosage suppressor of cdc45-10 led us to 
consider that a defect in origin firing in these cells might render the YEp vectors unstable, 
thereby contributing to the inability of these cells to grow on SC-ura media. If so, then 
this vector should also act as a partial HCS of tah11-10 cells. Indeed, of all the tah strains 
surveyed, HCS81 only suppressed the Top1T722A-hypersenitivity of cdc45-10, dpb11-10 
and tah11-10 strains (Fig. 2.14), consistent with a defect in the licensing and/or firing of 
origins for replication. 
The second dosage suppressor, HCS86 contains two complete ORFs and one 
partial ORF (Fig. 2.14). The complete ORFs are ADE8, which encodes a protein involved 
in adenine biosynthesis and SIZ1, which encodes a SUMO E3 ligase. The partial ORF is 
TRS120. Subcloning of HCS86 determined that a DNA fragment containing SIZ1 and a 
portion of ADE8 sufficed to partially restore cdc45-10 cellular resistance to Top1T722A-
induced DNA damage (data not shown). As with HCS81, the ability of HCS86 to dosage 
suppress the Top1T722A-dependent lethality of the other tah mutants was also assessed. 
However, in this case, only ubc9-10 cell viability was enhanced by HCS86 (Fig. 2.14).  
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Because HCS81 and HCS86 restored cell viability to different tah strains, they 
were independently transformed into the cdc45-10, dpb11-10 strain to determine if they 
could complement the temperature-sensitive phenotype of the double mutant at 36°C. As 
shown in Fig. 2.15, neither restored cell viability at 36°C. These findings further support 
the notion that the cdc45-10 defect responsible enhanced cell sensitivity to Top1T722A is 
distinct from the synthetic lethal interactions of cdc45-10 with dpb11-10. 
 
2.3.5 SUMO modification of Cdc45 
The isolation of SIZ1 as a high copy suppressor of cdc45-10 suggested that 
increased SUMO modification of a protein or proteins could alter cell sensitivity to Top1 
poisons. As diagrammed in Fig. 2.16, SUMO (small ubiquitin-like modifier) in 
mammalian cells or Smt3 in yeast is activated when a peptide tail is removed by the Ulp1 
protease to yield a mature di-Gly C terminus. A highly conserved SUMO E1 enzyme 
(Aos1/Uba2) initiates conjugation by first adenylating SUMO and then forming a 
covalent thioester bond between the C-terminus of SUMO and the active site Cys of the 
E1. The E1 then transfers SUMO to the catalytic Cys of the sole SUMO E2 conjugating 
enzyme, Ubc9. Next, either Ubc9 alone or in association with an E3 ligase (such as Siz1, 
Siz2, or Mms21) catalyzes the formation of an isopeptide linkage between the C-terminal 
carboxyl group of SUMO and the ε-amino group of the lysine in the target protein. 
Substrates can be de-SUMOylated by the action of the proteases Ulp1 or Ulp2. 
Modification of a target protein by SUMO can alter the protein’s subcellular localization, 
activity, stability or interactions with other proteins, to affect cellular processes such as 
gene transcription, apoptosis, cell cycle progression, chromatin organization and DNA  
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Fig. 2.15 Dosage suppressors of cdc45-10 are not able to restore cell viability to the 
cdc45-10, dpb11-10 double mutant strain at 36°C 
HCS81 and HCS86 were transformed into the cdc45-10, dpb11-10 double mutant strain 
and cell viability was assayed. Neither high copy suppressor could restore cell viability to 
the double mutant strain at 36°C. 
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Fig. 2.16 SUMOylation cycle 
SUMO is expressed as an inactive protein that becomes active when the protein tail is 
removed by the protease Ulp1. Active SUMO binds to the E1which transfers it to the E2, 
Ubc9. Ubc9 alone or with the help of an E3 conjugates SUMO to the lysine of the target 
protein. Target proteins can be de-sumoylated by the proteases Ulp1 or Ulp2. 
SUMOylation of a protein can affect protein localization or conformation, complex 
formation or protect from ubiquitin degradation. 
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repair. Ubc9 itself contains determinants of SUMO target recognition and binds directly 
to a consensus ΨΚX(D/E) motif, where Ψ is a hydrophobic residue, X is any amino acid 
and K is the lysine modified with SUMO. However, this specificity of Ubc9 is 
insufficient to account for the increasing number of SUMOylated proteins that are being 
reported and modification of nonconsensus SUMO sites has also been reported (32). An 
added complication of the analysis of protein SUMOylation is the transient nature of the 
SUMO linkage. For most targets, considerably less than 10% of the protein is modified at 
any given time, which makes SUMO target identification extremely difficult.  
The ability of SIZ1 to dosage suppress ubc9-10 sensitivity to Top1-induced DNA 
damage (32) was not surprising, as we had previously reported a decrease in global 
SUMO conjugation in ubc9-10 cells shifted to the non-permissive temperature (30). 
However, the results obtained with cdc45-10 cells prompted us to consider Cdc45 as a 
potential target of SUMOylation. Indeed, inspection of the primary amino acid sequence 
of S. cerevisiae Cdc45 revealed a consensus SUMO site located at Lys385. To assess if 
this site was an important determinant of temperature or drug sensitivity, CDC45 and 
cdc45-10 sequences were mutated, such that Arg was substituted for Lys 385. Vectors 
bearing wild-type CDC45, cdc45-10 and the corresponding SUMO mutants, cdc45SUMO  
and cdc45SUMO,G510R, respectively, were used in a plasmid shuffle in a cdc45Δ strain, as 
previously depicted in Fig. 2.8 and the effects of mutating K385 on cell sensitivity to 
high temperature, HU or CPT was assayed. As shown in Fig. 2.17, the viability of cells 
expressing cdc45SUMO versus Cdc45 was unaffected by high temperature (36°C) or 
exposure to HU or CPT at 36°C. In contrast, expression of cdc45SUMO,G510R further 
enhanced the slow growth phenotype and hypersensitivity to HU and CPT induced by 
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Fig. 2.17 Mutating the consensus SUMO site in Cdc45 enhances cdc45-10, but not 
CDC45, cell sensitivity to CPT or HU 
Cdc45, cdc45SUMO, cdc45-10 and cdc45SUMOG510R were shuffled in to the cdc45Δ 
plasmid shuffle strain and cell viability was assayed. Mutating the consensus SUMO site 
in Cdc45 did not alter cell sensitivity to CPT or HU. However, mutating the consensus 
SUMO site in cdc45-10 enhanced temperature sensitivity and sensitivity to CPT and HU. 
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cdc45-10 at 36˚C. These results suggest that mutation of the consensus SUMO site in 
Cdc45 does not alter cell sensitivity to CPT or HU; however, substitution of this Lys 
residue potentiates the defects in Cdc45G510R function responsible for the tah phenotype 
of cdc45-10 cells at 36°C. 
We next asked if the SUMO site mutation had any impact on the synthetic 
lethality of the double cdc45-10, dpb11-10 mutant. The vectors were transformed into 
cdc45-10, dpb11-10 cells and the viability of individual transformants was assayed at 
26°C and 36°C. As shown in Fig. 2.18, cdc45SUMO was not able to complement the 
synthetic lethal interactions of cdc45-10 and dpb11-10, suggesting that SUMO 
modification is required for the functional association of Cdc45 with Dpb11.  
 
2.4 DISCUSSION 
Cdc45 plays essential roles in DNA replication, both in the initiation of DNA 
replication and in processive DNA polymerization. In addition to recruiting replication 
factors necessary for origin firing, Cdc45 also acts as a processivity factor for the 
replicative Mcm2-7 helicase.  Indeed, chromatin immunoprecipitation of crosslinked 
Cdc45-DNA complexes, followed by queries of high density tiling arrays of yeast 
chromosome VI, demonstrate that Cdc45 is associated with ARS sequences in G1 phase 
of the cell cycle, yet tracks with the replication fork following origin firing. We 
previously reported that Cdc45 also plays a role in protecting cells from low levels of 
DNA damage induced by the CPT mimetic, Top1T722A. The conditional cdc45-10 
mutant harbors a single amino acid substitution, G510R, and is hypersensitive to CPT, HU 
and UV at 36°C. Upon shift to 36˚C in the absence of DNA damage, these cells exhibit a 
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Fig. 2.18 Cdc45SUMO did not restore cell viability to the cdc45-10, dpb11-10 double 
mutant strain 
Cdc45, cdc45SUMO, cdc45-10, cdc45SUMOG510R plasmids were transformed into the 
cdc45-10, dpb11-10 double mutant strain and cell viability was assayed at 26˚C and 
36˚C. cdc45SUMO, cdc45-10 or cdc45SUMO, G510R was not able to restore cell viability to 
the double mutant strain at 36°C.  
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transient defect in Okazaki fragment maturation. We previously reported that this mutant 
also exhibits a synthetic lethal interaction with another tah mutant, dpb11-10, which 
coincides with a persistent accumulation of Okazaki sized DNA fragments. The cdc45-10 
mutant also exhibits a slow growth phenotype when RAD9 is deleted suggesting that the 
damage accumulating in cdc45-10 cells is sensed by the Rad9 DNA damage checkpoint. 
Indeed, this mutant also exhibits synthetic lethal interactions with mrc1∆ and rad52∆ 
(data not shown), which is consistent with defects in processive DNA polymerization that 
require the Mrc1 checkpoint and homologous recombination for effective resolution of 
the Okazaki fragments.  
In these studies, we provide direct evidence that cdc45-10 is hypomorphic for 
cellular resistance to Top1-induced DNA damage, as increased gene dosage of the mutant 
allele restored cell resistance to low levels of Top1-DNA damage as well as the slow 
growth of this mutant at 36˚C. However, as cdc45-10 failed to dosage suppress the 
synthetic lethality of cdc45-10,dpb11-10 cells, these findings support a model whereby 
the functional interactions that are essential to maintain cell viability and Okazaki 
fragment maturation are distinct from the activity of Cdc45 needed to protect cells from 
Top1 poisons. Indeed, the results of the genetic screen for HCS of cdc45-10 cell 
sensitivity to Top1T722A also demonstrated that HCS81 and HCS86 failed to complement 
the temperature sensitive lethality of cdc45-10, dpb11-10 cells. An alternative 
explanation is that the shared defect in cdc45-10,dpb11-10 cells is more severe than that 
of cdc45-10 in the presence of wild-type DPB11, ergo the synthetic lethal phenotype. 
However we favor the former interpretation since mutation of Lys385 within the 
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consensus SUMO site in Cdc45 abolished cdc45-10,dpb11-10 cell viability, yet had no 
effect on cell sensitivity to Top1T722A or cell growth. 
Our attempts to develop epitope tagged versions of the Cdc45G510R mutant 
protein with which to assess alterations in Cdc45 levels, chromatin association, protein-
protein interactions, and subcellular distribution were unsuccessful. Nevertheless, these 
experiments clearly demonstrated that the C-terminal modifications of Cdc45G510R 
completely abrogated the essential function of this protein. These findings indicate a 
functional interaction between the C-terminus of Cdc45 and residues spanning Gly510. 
Since Gly is a very flexible amino acid, it is tempting to speculate that a change in protein 
architecture induced by the loss of Gly at this position is responsible for the tah 
phenotype of cdc45-10 cells. However, such considerations of mutant protein function 
will have to await the X-ray structure of Cdc45.   
The analysis of wild-type Cdc45 bearing a C-terminal HA tag also revealed some 
surprises. Although such constructs have been used extensively to assess Cdc45 
association with chromatin and it’s association with other cellular components, we found 
that Cdc45-HA was unable to suppress the synthetic lethality of cdc45-10,dpb11-10, 
while untagged Cdc45 did. These data demonstrate that the C-terminal HA residues 
altered the activity of Cdc45 in vivo. Moreover, these data raise the distinct possibility 
that additional functions for Cdc45 may yet be defined that are abolished or diminished in 
strains expressing Cdc45-HA. While the peptide-based antibodies generated in these 
studies were useful in assessing Cdc45 proteins in westerns blots, they proved ineffective 
in immunoprecipitation experiments. Thus, questions concerning alterations in mutant 
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Cdc45 interactions with Dpb11, Mcm5 or other components of the replication machinery 
will require the generation of additional antibodies.  
The isolation of HCS81 and HCS86 as dosage suppressors of cdc45-10 cell 
sensitivity to Top1T722A suggested specific defects in Cdc45G510R function. First, our 
determination that ARS1303 was responsible for the dosage suppression induced by 
HCS81 suggests a defect in origin licensing or firing in cdc45-10 cells. Indeed, the 
presence of two origins of replication (2µm and ARS1303) in the URA3 marked YEp 
vector also partially suppressed the tah phenotype of dpb11-10 and tah11-10. Since 
CDC45, DPB11 and TAH11 each provide essential functions in the initiation of 
replication, these findings suggest the mutants are defective in the replication and, 
therefore, the maintenance of plasmid DNA. The presence of an additional ARS may 
increase the likelihood of at least one origin firing per cell cycle. The temporal pattern 
and efficiency of ARS firing on yeast chromosome III have been well characterized. 
However, considerably less is known about ARS1303. Other ARS sequences were not 
isolated in our yeast HCS screen. Although the screen was not saturated, the sole 
isolation of ARS1303 raises the possibility that a unique feature of ARS1303 may be 
critical for this dosage suppression. Some origins, such as ARS305 fire early and 
efficiently in S-phase, while ARS309 fires late. ARS301 is a cryptic origin that only fires 
in Rad53 checkpoint defective strains exposed to DNA damaging agents. Whether any or 
all of these ARS sequences would also act as dosage suppressors of cdc45-10 or if 
ARS1303 function is uniquely enhanced by the defects in cdc45-10, tah11-10 or dpb11-
10 cells have yet to be defined. 
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In the case of HCS86, the ability of the SIZ1 to restore cdc45-10 or ubc9-10 cell 
viability in the presence of Top1T722A at 36°C suggests that SUMOylation of specific 
target proteins is required to protect cells from Top1 poisons. While mutation of the 
Cdc45 SUMO consensus site (Lys385) did not alter cell sensitivity to CPT or HU at 36°C, 
this mutation in the context of cdc45-10 enhanced the temperature sensitivity and CPT 
and HU sensitivity of these cells at 36°C. Moreover, Cdc45SUMO was not able to restore 
cdc45-10,dpb11-10 cell viability, suggesting that SUMO modification of Cdc45 is a 
critical determinant of the functional interaction of Cdc45 and Dpb11.  
Mutations in genes that encode proteins involved in the SUMO pathway have also 
been shown to induce cell cycle defects (40). For instance, yeast Smt3 (SUMO) was first 
identified in a screen for high copy suppressors of mutants of MIF2, which encodes a 
centromere binding protein. SUMO E1 (uba2-ts) and ubc9-ts mutants exhibit cell cycle 
defects and arrest at the G2/M boundary. On the other hand, SUMO modification of 
target proteins is typically very transient, such that only a small percentage of a given 
protein is SUMOylated at any one time. Thus, sensitive detection methods are often 
employed to ascertain whether a specific protein is actually SUMOylated, under a limited 
set of experimental conditions. Several large-scale proteomic analyses have identified 
SUMO substrates that are involved in many cellular processes including cell cycle, DNA 
replication, repair and recombination. For example, PCNA, the DNA polymerase sliding 
clamp, is SUMOylated in a cell cycle regulated manner, suggesting this modification is 
important for events occurring S-phase (41). SUMOylation of PCNA in response to DNA 
damage also promotes error-prone synthesis through recruitment of a translesion 
polymerase (42). DNA topoisomerase I itself has been shown to be modified by SUMO, 
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however, the consequence of this modification is debatable (30). Although our data 
implicate SUMOylation as a determinant of Cdc45 function, we have yet to ascertain 
whether Cdc45 itself is modified, or if SUMO conjugation of other replication proteins 
indirectly impacts the function of Cdc45 is protecting cells from Top1 poisons.  
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CHAPTER 3: CDC45 ORIGIN FIRING AND REPLICATION FORK 
PROGRESSION 
 
3.1 INTRODUCTION 
DNA replication is fundamental for the maintenance and growth of eukaryotic 
organisms (43). Chromosomal DNA must be replicated once and only once during         
S-phase to ensure the faithful transmission of genetic information to daughter cells (12). 
DNA replication is a complex process involving stringent regulatory mechanisms that 
couple replication to cell cycle progression (11). Failure to coordinate replication with 
cellular pathways such as cell cycle progression, checkpoints, recombination, repair and 
sister chromatid cohesion could result in chromosomal lesions or mutations leading to 
genomic instability, cell death or cancer (12).  
The budding yeast, Saccharomyces cerevisiae, has been proven to be a 
particularly tractable model system for identifying components of the DNA replication 
machinery due to the distinctive growth patterns that allow cell division cycle (cdc) 
phenotypes to be easily distinguished from defects in other cellular processes (44). In S. 
cerevisiae, DNA replication is initiated at restricted regions called autonomously 
replicating sequences (ARS). As diagrammed in Fig. 3.1, the six-subunit origin 
recognition complex (ORC) binds ARS throughout the cell cycle. At the end of mitosis 
the pre-replicative complex (pre-RC) consisting of the Mcm2-7 complex, Cdc6 and 
Tah11binds to ARS, licensing cells for DNA replication. As cells transition through late 
G1 phase, Cdc45 binds to the Mcm2-7 complex. As the pre-RC and initiation complexes 
are assembled, the cyclin dependent kinases, Cdc28/Clb5/Clb6 and Cdc7/Dbf4, become 
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Fig. 3.1 DNA replication 
At the end of mitosis a decrease in Cdk-Clb kinase activity allows pre-replicative 
complex formation consisting of Orc, Mcm2-7, Tah11 and Cdc6. Cells pass through 
“START” in G1-phase committing them to DNA replication. As cell begin to transit from 
late G1 to S-phase Dbf4-Cdc7 and Clb5/6-Cdc28 protein kinases become active and 
phosphorylate components of the pre-RC promoting the recruitment of Cdc45 and GINS.  
Once DNA replication is initiated, Dpb11 recruits Pol ε and facilitates the switch between 
Pol α and Pol ε. Mcm2-7, GINS and Cdc45 move with replication forks as elongation 
occurs. 
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active and phosphorylate components of the pre-RC and Cdc45 resulting in stable 
protein-protein interactions (45). In particular, the binding of the GINS complex 
stabilizes the association of Cdc45 with Mcm2-7 to facilitate the processive activity of 
the replicative helicase during the elongation phase of DNA replication.  
Cdc45 is an essential protein that is required for the initiation and elongation steps 
of DNA replication. The binding of Cdc45 to the Mcm2-7 complex at the origin is a 
critical event for origin firing. Following Cdc45 binding and initiation of replication, the 
origin DNA unwinds allowing the replicative machinery to bind and synthesis to 
progress. The initial step in elongation is the synthesis of a short RNA primer laid down 
by Polα primase. Polα is then replaced with the more processive polymerases delta (Δ) 
and epsilon (ε) through the action of PCNA, the “sliding clamp” processivity factor and 
replication factor C (Rfc), the clamp-loading complex. DNA is synthesized as leading 
and lagging strands. Leading strand synthesis is very efficient and highly processive, 
while lagging strand synthesis requires multiple cycles of priming and extension.  
Lagging strand synthesis results in Okazaki fragments that must be processed by 
nucleases and DNA ligase to create a single DNA chain.  To protect the underlying DNA 
and ensure completion of DNA synthesis, leading and lagging strand synthesis remains 
coupled throughout synthesis (10). 
Two-dimensional neutral/neutral gel (2-D gel) electrophoresis has been 
extensively used to describe the conformational changes that occur in replication 
intermediates during the initiation and elongation steps of DNA replication (12). This 
method was derived by analyzing circular DNA on agarose gels and demonstrated that 
different shapes of a DNA molecule influences its electrophoretic mobility. Supercoiled 
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and nicked circular DNA have mobilities that differ from linear molecules of the same 
mass. Branch molecules also run irregularly in agarose gels and this is influenced by the 
agarose concentration and the strength of the electric field (46). Based on these 
properties, Bell and Byers developed the 2D agarose gel method to separate linear 
molecules from branched intermediates (47). The first dimension gel is run under 
conditions that minimize the effect of molecular shape and separates molecules according 
to their mass.  The second dimension gel is run under conditions that emphasize the effect 
of shape and separates the molecules accordingly (46,48). 
The first step in analyzing replication intermediates in 2D gels involves enriching 
the samples with replication intermediates by synchronizing the cells in G1 phase and 
harvesting the DNA during S-phase. The DNA molecules isolated are delicate branched 
molecules and precautions must be taken in order to preserves the integrity of the DNA at 
the fork. As described in Fig. 3.2, the genomic DNA is digested with restriction enzymes 
to create fragments specific to the chromosomal regions of interest.  These fragments are 
run in a low percentage first dimension gel. The portion of the first dimension gel 
containing the restriction fragments of interest is cut, rotated 90° and embedded in a 
higher percentage agarose second dimension gel. Electrophoresis is carried out in the 
presence of ethidium bromide to aid in separating the shapes of the replication 
intermediates. Following electrophoresis, the gel is subjected to Southern blotting and the 
membrane is hybridized with a 32P labeled probe in order to visualize the replication 
intermediates at origins or surrounding chromosomal regions of interest (46). Fig. 3.3 
diagrams the shapes of restriction fragments derived from replicating DNA. The 1n spot 
located on the linear molecule line represents non-replicating molecules. Replication  
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Fig. 3.2 Replication intermediate isolation and viualization by 2-D gel 
electrophoresis 
Cells are synchronized in early G1 and released into S-phase. Genomic DNA is extracted 
from replication intermediates, restriction digested with HindIII and EcoRV and 
separated by size in the first dimension. Fragments of 3.5 Kb and larger are excised from 
the first dimension, rotated 90˚, and separated in the second dimension by shape. Second 
dimension gels are blotted and probed for regions of interest on chromosome III. 
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Fig. 3.3 Shapes of replication intermediates 
Non-replicating molecules are represented by a 1n spot located on the linear molecule 
line. Replication that is initiated within a restriction site results in a series of bubble 
shaped molecules representing initiation of bi-direction replication forks. A restriction 
fragment lying between an origin and the terminus results in a series of Y shaped 
molecules formed as a single replication fork moves through the restriction fragment. A 
2n spike or X-spike represents the shape of recombination intermediates. 
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initiated within a restriction site results in a series of bubble shaped molecules 
representing initiation of bi-direction replication forks. A restriction fragment lying 
between an origin and the terminus results in a series of Y shaped molecules formed as a 
single replication fork moves through the restriction fragment. A 2n spike or X-spike 
represents the shape of recombination intermediates. 
The isolation of the cdc45-10 hypomorphic allele that conferred hypersensitivity 
to the CPT mimetic, Top1T722A, supported a role for Cdc45 in protecting cells against 
Top1-DNA damage. Because Cdc45 is essential for the initiation and elongation steps of 
DNA replication, assessing origin firing and replication fork progression in cdc45-10 
cells provided a unique opportunity to assess whether Cdc45G510R was defective in either 
of these two fundamental steps. Indeed, using 2-D agarose gel analysis, we report that 
Cdc45G510R caused a decrease and a delay in origin firing at ARS305 when cdc45-10 
cells were shifted from 26˚C to 36˚C after release from α-factor arrest, with no apparent 
alterations in replication fork progression. These results contrasted with the fragility of 
the replication forks that was observed when cdc45-10 cells were shifted to the non-
permissive temperature prior to cell cycle arrest in G1-phase. Under these conditions, the 
licensing of origins at 36˚C impaired the stability of the replication forks in S-phase. 
Thus, Cdc45 function is required to ensure the timely firing of an early replication origin 
and for the appropriate assembly of the replication machinery necessary to support 
processive replication. 
 
 
 
71 
3.2 EXPERIMENTAL PROCEDURES 
 
3.2.1 Chemicals and yeast strains 
The mating pheromone α-factor, purchased from US Biological, was stored at       
-20˚C at 1mg/ml in methanol and used at a final 5μg/ml or 10μg/ml. 
S. cerevisiae strains, cultured using standard conditions, were CSY6 (MATa, 
ura3-52, his3Δ200, leu2Δ1, TRP1) and CLY16 (MATa, ura3-52, his3Δ200, leu2Δ1, 
TRP1, TOP1, cdc45-10). 
 
3.2.2 Analysis of cell cycle progression and 2-D gel electrophoresis of replication 
intermediates 
Asynchronous cultures of isogenic CDC45 and cdc45-10 cells, exponentially 
growing at 26˚C, were diluted to an OD=0.3, then treated with 5 µg/ml α-factor to induce 
cell cycle arrest in G1 phase. After 60 minutes the cells were shifted to 36˚C and an 
additional 2.5 µg/ml α-factor was added, when greater than 95% of the cells exhibited a 
schmoo phenotype indicative of α-factor arrest, the cells were released into S-phase by 
filtration and resuspended in media pre-warmed to 36˚C. Alternatively, cells cultured at 
36˚C, were arrested with 10 µg/ml a-factor for 60 minutes, and treated with an additional 
5 µg/ml α -factor for 60 minutes. As above, cells were then released into S-phase in 
media pre-warmed to 36˚C. At the times indicated, aliquots of the cells were collected by 
centrifugation for western blot analysis (see below) or fixed with 100% ethanol and 
processed for FACs analysis as described (49). 
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Replication intermediates were also purified at 0 min, 10 min, 20 min, 40 min, 60 
min, or 80 min following release of cells from α-factor into YPD as described (12). To 
analyze ARS305, ARS305+6Kb, ARS305+18Kb or ARS305+29Kb replication 
intermediates, purified DNA, restricted with Eco RV and Hind III, was resolved by 2-D 
gel electrophoresis, transferred to nylon membranes, successively hybridized with 32P-
labeled probes spanning ARS305, ARS305+6Kb, ARS305+18Kb or ARS305+29Kb and 
visualized by PhosphorImage analysis. The probes were first PCR amplified from 
genomic DNA (primer pairs available upon request), then α-32P-dATP labeled using a 
Megaprime DNA Labeling kit from Amersham. 
 
3.2.3 Western blot analysis 
To assess Cdc45 and Cdc45G510R protein levels, NaOH/TCA extracts were 
prepared from cells following release from α-factor as described (30). Cdc45 proteins 
were detected by immunoblotting with a rabbit polyclonal Cdc45 antibody, followed by 
an HRP-conjugated donkey anti-rabbit antibody and chemiluminescence (Pierce). 
Immunostaining with tubulin antibodies served as loading controls. 
 
3.3 RESULTS 
Cdc45 is required for the initiation and elongation phases of DNA replication. We 
previously reported that cdc45-10 mutant cells were hypersensitive to Top1-induced 
DNA damage. These cells also exhibited a transient accumulation of Okazaki-sized DNA 
fragments upon shift to the non-permissive temperature that suggested a defect in 
processive DNA replication. While these findings suggested that alterations in 
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Cdc45G510R function impaired the elongation of phase of DNA replication, they failed to 
define the exact nature of this defect. To more precisely address this question, we used 2-
D agarose gel electrophoresis to investigate the efficiency of origin firing and replication 
fork progression in cdc45-10 cells. To discriminate between defects in origin licensing in 
G1-phase and processive DNA replication in S-phase, two experimental approaches were 
taken.  
As diagrammed in Fig. 3.4A, to address Cdc45 function in the elongation phase of 
DNA replication, the cells were α-factor arrested in G1 phase of the cell cycle at the 
permissive temperature of 26˚C, then released into S-phase at 36˚C. Under these 
conditions, Cdc45G510R function in origin licensing would occur at the permissive 
temperature, while DNA replication would be initiated at the non-permissive temperature 
for Cdc45G510R. This contrasts with the experimental design diagrammed in Fig. 3.4B, 
where the mutant and wild-type cells are shifted to 36˚C prior to α-factor arrest in G1-
phase. In this case, both origin licensing and replication occur at the non-permissive 
temperature for Cdc45G510R. A comparison of these data would then allow us to define 
the consequences of defects in Cdc45 function in both phases of the cell cycle. 
At the permissive temperature of 26˚C, cdc45-10 cells exhibit a subtle slow growth 
phenotype in the absence of exogenous DNA damage, which corresponds to a slight 
delay in S-phase transit relative to isogenic wild-type cells cultured under the same 
conditions (data not shown and the FACs profiles shown in Fig. 3.5). However, a survey 
of several ARSs, including ARS305 and ARS607, failed to reveal any obvious defect in 
origin firing (data not shown). However, this was not the case when cdc45-10 cells were 
either shifted to 36˚C prior to S-phase transit, or cultured at 36˚C. 
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Fig. 3.4 Experimental approaches for defining defects in origin licensing in G1-
phase and processive DNA replication in S-phase 
(A) CDC45 and cdc45-10 cells were cultured at 26˚C, synchronized in late G1-phase 
using α-factor and released into S-phase at 36˚C.  
(B) CDC45 and cdc45-10 cells were cultured at 36˚C, synchronized in late G1-phase 
using α-factor and released into S-phase at 36˚C. 
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Fig. 3.5 CDC45 and cdc45-10 S-phase transit at 26˚C and 36˚C 
At 26˚C, cdc45-10 cells exhibit a subtle slow growth phenotype in the absence of 
exogenous DNA damage compared to CDC45, however, when cdc45-10 cells were 
shifted to 36˚C, the slow S-phase transit was exacerbated. 
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In the first case, i.e., following synchronization in late G1 at 26˚C, CDC45 and 
cdc45-10 cells were shifted to 36˚C upon release into S-phase. Aliquots of cells were 
collected at time 0, 10, 20 and 40 minutes following α-factor release. The replication 
intermediates were extracted, digested with restriction enzymes specific for the regions of 
interest on chromosome III and separated in an agarose gel on the basis of size. The 
portion of the first dimension gel containing restriction fragments of 3.5 kilobases (Kb) 
and larger were excised, rotated 90° and the replication intermediates were then separated 
in the second dimension on the basis of shape. The DNA was then transferred to a nylon 
membrane and successively hybridized with 32P-labeled probes specific for regions 
spanning the left arm of chromosome III. The temporal pattern of ARS firing and 
replication fork progression have been extensively characterized for chromosome III. In 
wild-type cells, bi-directional DNA replication initiates at ARS305 early in S-phase. 
Towards the left telomeric end of chromosome III, the remaining ARS elements, 
ARS301-304, are cryptic and rarely fire. Thus, the timing of origin firing and the 
progression of a lone replication fork that uniquely originates at ARS305 can be assessed 
as the cells synchronously transit S-phase.  
As shown in Fig. 3.6, following release into S-phase, CDC45 cells exhibited 
prominent firing of ARS305 by 10 minutes, as evidenced by the appearance of a bubble 
arc (arrow). In the FACs profiles of these cells, shown in Fig. 3.5, the cells accumulated a 
2n DNA content by 40 minutes. This time frame also coincided with a second, less 
intense round of DNA replication at ARS305 (Fig. 3.6), as the cells lose synchrony. These 
data contrast with those obtained with cdc45-10 cells. As seen in Fig. 3.6, there was a 
delay in the timing of ARS305 firing, as well as the extent of origin firing. A bubble arc  
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Fig. 3.6 Alterations in Cdc45 function delays and decreases early origin firing but 
does not affect replication fork progression 
CDC45 and cdc45-10 cells were grown at 26˚C, synchronized in late G1 with α-factor 
and released into S-phase a 36˚C. Replication intermediates were visualized using 2-D 
gel electrophoresis, blotted and probed for ARS305, ARS305 + 6Kb and ARS305 + 18Kb. 
cdc45-10 cells exhibit a delay and decrease in origin firing at ARS305 compared to 
CDC45 cells. However, successive stripping and re-probing of the blots for regions 6Kb 
and 18Kb away from ARS305 revealed that replication fork progression in cdc45-10 cells 
was similar to that observed in CDC45 cells. 
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was not detected until 20 minutes following release into S-phase and the signal was 
consistently weaker than that observed with CDC45 cells. However, when the blots were 
stripped of the ARS305 probe and re-probed for sequences 6Kb or 18Kb towards the left 
telomeric end of the chromosome, the replication forks appeared to progress with the 
same kinetics as those detected in CDC45 cells. This decrease in the timing and 
efficiency of ARS305 firing coincided with a more pronounced decrease in S-phase 
transit at 36˚C, as seen in the FACs profiles of Fig. 3.5. These data suggest that the 
alterations in Cdc45G510R function in S-phase are restricted to the initiation of DNA 
replication. However, this cdc45-10 phenotype could not be attributed to the selective 
thermolability of the Cdc45G510R protein in S-phase upon shift to 36˚C. Indeed as seen in 
Fig. 3.7, there was actually an increase in steady state levels of Cdc45G510R protein, 
relative to wild-type Cdc45 protein, when cells were released into S-phase. Whether the 
mutant protein exhibits alterations in chromatin association, and how this might impact 
Cdc45 protein turnover has yet to be addressed. Nevertheless, the replication defects in 
cdc45-10 cells are not a consequence of Cdc45G510R down regulation at the non-
permissive temperature.  
We next considered the consequences of licensing ARS305 at the non-permissive 
temperature, as diagrammed in Fig. 3.4B. In these experiments, CDC45 and cdc45-10 
cells were cultured at 36°C, then synchronized in late G1 phase with α-factor and 
released into S-phase at 36°C. Aliquots of cells were collected at 0, 10, 20, 40, 60, and 80 
minutes after α-factor release and the replication intermediates were resolved as above. 
As shown in Fig. 3.8, the temporal pattern of ARS305 firing in CDC45 cells was similar 
to that observed in Fig. 3.6. A prominent bubble arc was detected by 10 minutes  
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Fig. 3.7 cdc45-10 cells exhibit increased protein levels when origins are licensed at 
26˚C and S-phase transit occurs at 36˚C 
CDC45 and cdc45-10 cells were cultured at 26˚C, α-factor arrested and released into S-
phase at 36˚C. Time points were collected; whole cell extracts were prepared and 
visualized on western blots using a Cdc45 antibody and a tubulin antibody as a control. 
cdc45-10 cells exhibited an increase in protein level compared to CDC45 cells. 
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Fig 3.8 Licensing ARS305 at 36˚C alters replication fork stability in cdc45-10 cells 
CDC45 and cdc45-10 cells were grown at 36˚C, synchronized in late G1 with α-factor 
and released into S-phase a 36˚C. Replication intermediates were visualized using 2-D 
gel electrophoresis, blotted and probed for ARS305. The intermediates isolated from 
cdc45-10 cells were distributed along a linear diagonal with a DNA mass between 1n and 
2n, implying initiation at ARS305 however, the intermediates failed to retain differences 
in shape. 
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following release from S-phase. In this case, a second round of replication was not 
evident at later times due to a rapid loss of cell cycle synchrony (data not shown). 
However, the results obtained with cdc45-10 cells were rather remarkable. In contrast to 
the canonical distribution of replication intermediates along bubble and y-arcs, the 
intermediates isolated from cdc45-10 cells cultured at 36˚C were distributed along a 
linear diagonal with a DNA mass between 1n and 2n. Thus, although DNA replication 
had initiated at ARS305 to yield a greater than 1n DNA content, the intermediates failed 
to retain differences in shape. Replication fork stalling in vivo is typified by the 
accumulation of a discreet spot along the Y-arc, while replication fork collapse in vivo 
has been described as an increase in cone and X-spike signals, with a concomitant 
decrease in bubble and Y-arcs (50). Rather, the pattern obtained in Fig. 3.8 is consistent 
with replication fork collapse during the isolation of the intermediates. Indeed, this 
interpretation is consistent with the extended tails emanating from the spots in 0, 10 and 
20’ samples. Hybridization of this blot with the ARS305 + 6Kb probe revealed a similar, 
albeit weaker, pattern of spots with very faint Y-arcs discernible in some samples (data 
not shown). The fragility of these replication intermediates is also mirrored in the FACs 
profiles, which demonstrate a board distribution of cells throughout S-phase (data not 
shown), as opposed to the tight distributions that mark the S-phase transit of cdc45-10 
cells in Fig. 3.5. However, as in cdc45-10 cells shifted to 36˚C, Cdc45G510R protein 
levels in cells cultured at 36˚C were also elevated in S-phase, relative to wild-type Cdc45 
protein levels (Fig. 3.9). Taken together, these data indicate that licensing of origins in 
cdc45-10 cells at 36˚C altered the assembly of stable replication forks in the subsequent 
S-phase, while the assembly of pre-RC complexes at 26˚C, followed by a shift to 36˚C as 
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Fig. 3.9 cdc45-10 cells exhibit elevated protein levels when origin licensing and S-
phase transit occurs at 36˚C 
CDC45 and cdc45-10 cells were cultured at 36˚C, α-factor arrested and released into S-
phase at 36˚C. Time points were collected; whole cell extracts were prepared and 
visualized on western blots using a Cdc45 antibody and a tubulin antibody as a control. 
cdc45-10 cells exhibited an increase in protein level compared to CDC45 cells. 
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cdc45-10 cells entered S-phase, only affected the temporal pattern and efficiency of 
origin firing.  
 
3.4 DISCUSSION 
The cdc45-10 hypomorphic mutant was isolated in a yeast genetic screen for 
conditional mutants exhibiting enhanced sensitivity to low levels of DNA damage 
induced by Top1T722A, a mutant enzyme that acts as a CPT mimetic. Cdc45 is an 
essential protein that functions in the formation of pre-RC complexes in late G1 phase, in 
the recruitment of replication machinery components to initiate DNA replication and as a 
processivity factor for the replicative Mcm2-7 helicase during the elongation phase of 
DNA replication. Cdc45 lacks any identifiable enzymatic activity and any similarity to 
known protein structural domains, other than a Cdc45-motif found in other members of 
this conserved protein family. Thus, Cdc45 appears to function as a scaffold for the 
assembly/recruitment of replication machineries.  
Our previous characterization of cdc45-10 cells defined a single G510R 
substitution in Cdc45 that conferred the synthetic lethal interactions of this mutant with 
defects in Dpb11 function, the Rad9 DNA checkpoint and the Rad52 homologous 
recombination pathway (data not shown) (22). Low resolution alkaline sucrose gradient 
analyses indicated a transient accumulation of Okazaki-sized DNA fragments in cdc45-
10 cells upon shift to the non-permissive temperature, which was exacerbated in the 
double cdc45-10,dpb11-10 mutant. These data suggested a common defect in polymerase 
switching induced the synthetic lethality of the double mutant strain (22). However, our 
recent studies of dosage suppressors in Chapter 2 demonstrate that the alterations in 
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Cdc45G510R function, which enhance cell sensitivity to Top1 poisons, are distinct from 
those that induce the synthetic lethality with dpb11-10. 
Indeed, our analysis of origin firing and fork progression in synchronized cdc45-
10 and CDC45 cells cultured under various conditions demonstrate distinct alterations in 
Cdc45G510R function in the assembly of the replication machinery and the temporal 
regulation of origin firing. In G1-phase, when pre-RC assembly, i.e., licensing of a 
replication origin, occurs at the non-permissive temperature for Cdc45G510R, the 
replication forks assembled in the subsequent S-phase at 36˚C were quite fragile. This 
phenotype was evident in the broad S-phase distribution of these cells (data not shown) 
and the collapse of the replication intermediates during purification (Fig. 3.8). The 
fragility of these intermediates precluded any assessment of the relative timing of 
ARS305 firing or of the rate of replication fork progression. Nevertheless, the instability 
of these complexes contrasted with the stable replication intermediates isolated from 
cdc45-10 cells that were shifted to 36˚C following release from α-factor arrest. Thus, the 
assembly of replication forks at 36˚C per se had no adverse effect on fork stability. This 
interpretation of the data is further supported by the relatively tight distribution of cdc45-
10 cellular DNA content as cells transit S-phase at 36˚C in Fig. 3.5. Rather, these results 
suggest that alterations in pre-RC assembly, due to specific defects in Cdc45G510R 
function at 36˚C, impair the subsequent assembly of the replication machinery in S-
phase. Cdc45 has been shown to physically interact with Mcm5; thus, it is tempting to 
speculate that alterations in Cdc45G510R binding to Mcm5 could impact fork stability 
through alterations in helicase activity. Unfortunately, a rigorous assessment of 
Cdc45G510R interactions with other components of the pre-RC will have to await the 
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development of antibodies capable of immunoprecipitating Cdc45G510R, as described in 
Chapter 2. Nevertheless, such decreases in fork stability provide a mechanistic basis for 
the synthetic lethal interactions with rad9∆ and rad52∆ mutants, as a functional DNA 
damage checkpoint and homologous recombination, respectively, would enhance cell 
survival by affecting the repair of collapsed forks. The assembly of fragile forks would 
also enhance cell sensitivity to Top1 poisons, either as a consequence of direct collisions 
between the replication machinery and the stabilized Top1-DNA complexes or the local 
accumulation of positive supercoils in advance of the fork (8,51,52). 
The formation of pre-RC at the permissive temperature, followed by S-phase 
transit at the non-permissive temperature, revealed a role for Cdc45 in the timing and 
efficiency of ARS305 firing. These findings suggest that the isolation of ARS1303 as a 
weak dosage suppressor of cdc45-10 cell sensitivity to TopT722A (reported in Chapter 2), 
may reflect an increase in plasmid DNA stability, rather than a direct effect on 
Top1T722A-induced DNA damage. Whether dpb11-10 cells also exhibit similar defects in 
origin firing has yet to be determined. Nevertheless, the ability of ARS1303 to dosage 
suppress dpb11-10 and tah11-10 sensitivity to Top1T722A does imply a common 
mechanism of suppression. However, the transient accumulation of Okazaki-sized DNA 
fragments observed in both cdc45-10 and dpb11-10 cells (22) upon shift of asynchronous 
cells to 36˚C, also suggests a common defect in fork stability. Indeed, as will be 
discussed in Chapter 4, such mutation-induced alterations in fork stability would not only 
enhance cdc45-10 and dpb11-10 cell sensitivity to Top1 poisons, such as CPT, but would 
also exacerbate the adverse effects that rapamycin inhibition of TORC1 has on S-phase 
progression. 
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CHAPTER 4: RAPAMYCIN-INDUCED ALTERATIONS IN                
S-PHASE TRANSIT 
 
4.1 INTRODUCTION 
As described in Chapter 2, a yeast genetic screen was used to isolate conditional 
mutants that exhibit enhanced sensitivity to the self-poisoning Top1T722A mutant. 
Several of these mutants, including hypomorphic alleles of CDC45 and DPB11, exhibit 
alterations in DNA replication, which exacerbate the S-phase-dependent toxicity of the 
Top1 poison, camptothecin. Surprisingly, many of these mutants were also hypersensitive 
to the macrocyclic lactone antibiotic rapamycin (RAP) (53). RAP, in complex with 
FKBP12, specifically targets TOR (target of rapamycin), a phosphatidylinositol 3-kinase-
related kinase family member that regulates cellular responses to a wide range of 
environmental stresses such as nutrient starvation, growth factor deprivation and hypoxia. 
These signals are transmitted by multi-protein complexes through a variety of 
downstream pathways to regulate cap-dependent mRNA translation, transcriptional stress 
responses, G1 to S-phase transition and cell survival (54-56). The dysregulation of Akt-
TOR signaling has been associated with tumorigenesis, therefore, this pathway provides 
potential targets for cancer chemotherapy (54,57). Currently RAP analogs are being 
developed in clinical oncology trials. 
The TOR kinase was initially identified from a genetic screen in S. cerevisiae for 
mutants conferring resistance to RAP. In S. cerevisiae there are two closely related Tor1 
and Tor2 kinases, while other eukaryotic genomes encode a single kinase, as exemplified 
by mammalian mTOR (56). As in mammalian cells, TOR signaling in yeast regulates cell 
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growth through the function of distinct multi-protein complexes as seen in Fig. 4.1 
(56,58-60). In yeast, Tor1 or Tor2 is a component of a RAP-sensitive TOR1 complex 
(TORC1) consisting of Kog1, Lst8 and Tco89. Mammalian TORC1 consists of mTOR, 
raptor (a Kog1 analog) and mLst8. Under favorable environmental conditions, TORC1 
regulates the accumulation of cell mass by controlling the translation initiation of a 
limited subset of capped mRNAs, nutrient uptake and ribosome biogenesis. RAP 
treatment or depriving cells of nutrients or essential growth factors induces a starvation 
response characterized by decreased protein synthesis, macroautophagy and the induction 
of stress response transcription factors (56). 
A second complex, TORC2, is RAP “insensitive” and is involved in regulating 
actin cytoskeletal organization during cell growth, endocytosis and calcineurin and 
sphingolipid signaling. Although in some cells, TORC2 is also inhibited as a 
consequence of long-term exposure to rapamycin (61). Yeast TORC2 consists of Tor2 in 
complex with other conserved proteins such as Avo3 (rictor in mammalian cells) 
(56,62,63). 
The PI3K-related kinase family members ATM, ATR, DNA-PK, yeast Mec1 and 
Tel1 have significant roles in repair and checkpoint responses to DNA damage (64). 
Although a direct role for TOR signaling in S-phase has yet to be defined, several 
observations suggest that TORC1 may function in response to DNA replication stress. 
For example, when p53-/- mouse embryo fibroblasts or cancer cells mutant for p53 are 
cultured under serum free conditions, RAP treatment induces apoptosis, which coincides 
with entry into S-phase (65,66). Second, RAP inhibition of mTOR signaling has been 
shown to enhance the cytotoxic activity of the DNA damaging agent cisplatin (67,68). 
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Fig. 4.1 The TOR pathway 
The TOR pathway regulates cellular response to environmental stress such as nutrient 
starvation, growth factor deprivation and hypoxia. TOR1 or TOR2 can form a rapamycin 
sensitive TORC1 complex involved in regulating cap-dependent translation, 
transcriptional stress responses, cell cycle progression from G1 to S-phase and cell 
survival. TOR2 can for a rapamycin insensitive TORC2 complex involved in actin 
organization. 
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Although, the underlying mechanisms affecting cell survival in S-phase remain unclear. 
A third line of evidence derived from our studies of the hypomorphic alleles of CDC45 
and DPB11 that are hypersensitive to Top1T722A-induced DNA damage and exhibit 
alterations in DNA replication (22,30,34). These mutants are also hypersensitive to RAP 
implying that TOR signaling plays a role in S-phase. 
In this study we report that rapamycin-sensitive TORC1 signaling functions to 
promote S-phase transit and maintain cell viability following Rad53 checkpoint 
activation by DNA damage or replicative stress. In response to MMS-induced DNA 
damage, TORC1 signaling was required to maintain the stability of stalled replication 
forks independent of the Rad53 checkpoint. In contrast, in response to hydroxyurea (HU) 
induced replication stress, TORC1 functioned to promote fork progression while cell 
viability and replication fork stability were maintained by the Rad53 checkpoint. Thus, 
TORC1 signaling appears to play distinct roles in S-phase in mediating cellular responses 
to DNA lesion versus the prolonged stress imposed on the replication machinery by HU. 
 
4.2 EXPERIMENTAL PROCEDURES 
 
4.2.1 Chemicals and yeast strains 
Hydroxyurea (HU) was purchased from U.S. Biological. RAP, obtained from the 
NCI drug repository, was dissolved in dimethyl sulfoxide, and stock solutions of 1 mg/ml 
were stored at -20˚C. The mating pheromone α-factor, from Diagnostic Chemicals Ltd, 
was stored at -20˚C at 1 mg/ml in methanol and used at a final concentration of 5 μg/ml. 
MMS was purchased from Sigma. 
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S. cerevisiae strains, cultured under standard conditions, were CSY6 (MATa, 
ura3-52, his3Δ200, leu2Δ1, TRP1) and CSY75 (MATa, ura3-52, his3Δ200, leu2Δ1, 
sml1Δ::His3, rad53Δ::TRP1) 
 
4.2.2 Cell cycle analysis and viability assays 
MATa cells, a-factor arrested in G1 phase of the cell cycle, were washed by 
filtration and released into medium alone, or medium supplemented with 200 ng/ml RAP, 
0.05% MMS, 0.05% MMS plus 200 ng/ml RAP  (MMS + RAP), 10 mg/ml HU, or 10 
mg/ml HU plus 200 ng/ml RAP (HU + RAP). Isogenic strains prototrophic for 
tryptophan synthesis were used to avoid the complications of RAP-induced down 
regulation of the Tryptophan transporter. For cell viability assays, aliquots of the cells 
were washed by centrifugation at the times indicated, to remove the drugs, serially ten-
fold diluted and plated to determine clonogenic survival at 30˚C. Aliquots of the cells 
were also fixed with 70% ethanol and stored at 4˚C for subsequent FACs analysis.  
 
4.2.3 2-D gel analysis of replication intermediates 
Replication intermediates were purified at the indicated times following release of 
the cells from α-factor into YPD or YPD plus RAP, MMS, MMS+RAP, HU or HU + 
RAP as described (12). To analyze ARS305 replication intermediates, purified DNA, 
restricted with Eco RV and Hind III, were resolved by 2-D gel electrophoresis, 
transferred to nylon membranes, hybridized with a 32P-labeled probe spanning ARS305 
and visualized by PhosphorImage analysis. To assess replication fork progression along 
the left arm of chromosome III, the same blots were successively stripped and re-probed 
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with radiolabeled DNA derived from genomic sequences 6Kb, 18Kb or 29Kb from 
ARS305. 
 
4.3 RESULTS 
 
4.3.1 TOR signaling is a determinant of cell survival in response to DNA damage 
RAP inhibition of TOR signaling induces yeast cell cycle arrest in early G1 phase, 
which precedes the G1 block induced by the α-factor mating pheromone (69). Therefore, 
as diagrammed in Fig. 4.2, we reasoned that TOR signaling in S-phase could be assessed 
by first arresting cells in late G1 phase with the mating pheromone α-factor, then 
releasing cells into media containing RAP, in the presence or absence of the DNA-
damaging agent MMS or the ribonucleotide reductase inhibitor HU.  
We, and others, have reported that when cells are released into media containing 
RAP a subpopulation of α-factor arrested cells failed to transit S-phase (data not shown, 
(53,69). However, our studies demonstrated that the kinetics of S-phase transit for those 
cells that entered S-phase mirrored those of the untreated control cells with RAP-treated 
cells accumulating in the next G1 phase. When cells were released into media containing 
MMS, S-phase transit was decreased due to the activation of the Rad53 checkpoint. This 
effect on S-phase transit has been well documented. However, our results demonstrate 
that RAP treatment further delayed the slow S-phase transit induced by MMS (data not 
shown). As shown in Fig. 4.3, under the same conditions, RAP treatment alone was 
growth inhibitory not cytotoxic. In contrast, the cytotoxicity of MMS was enhanced by 
co-treatment with RAP (compare MMS with MMS+RAP in Fig. 4.3). Thus, the further 
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Fig. 4.2 Experimental design for assessing TOR signaling in S-phase 
Asynchronous cultures were α-factor arrested in late G1-phase. The cultures were 
released into S-phase into media as a control, MMS, rapamycin and MMS + rapamycin 
to assess S-phase transit. 
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Fig. 4.3 Rapamycin inhibition of TOR signaling decreases cell viability in response 
to MMS treatment 
Arrested cells were released into media with no drug, RAP, MMS or MMS + RAP. The 
cells were serially diluted at the times indicated and the number of viable cells forming 
colonies on YPD plates following incubation at 30˚C was plotted relative to time=0. 
Error bars indicate standard deviations (n=3). 
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delay in S-phase transit induced by MMS+RAP over that observed with MMS alone was 
reflected in a proportional decrease in colony number over time. 
We recently reported that TORC1 acts as a survival pathway in response to 
genotoxic stress, in part, by maintaining the elevated expression of the ribonucleotide 
reductase subunits Rnr1 and Rnr3 induced by DNA damage activation of the Rad53 S-
phase checkpoint (53). Our findings supported a model whereby TORC1 acts as a 
survival pathway in response to DNA damage by maintaining the deoxynucleoside 
triphosphate pools necessary for error-prone translesion DNA polymerases. In fact as 
diagrammed in Fig. 4.4, TOR-dependent cell survival in response to DNA damaging 
agents coincides with increased mutation rates. Thus, one consequence of TORC1 
signaling in the face of persistent DNA damage may be the acquisition of mutations that 
confer drug resistance. However, the pronounced delay in S-phase transit induced by 
MMS+RAP also led us to consider the effects that inhibiting TORC1 signaling might 
have on the stability of the replication forks. 
 
4.3.2 Replication fork stability is diminished by MMS + RAP 
To assess origin firing and fork stability in cells treated with MMS +/- RAP, 
replication intermediates resolved in 2-D gels, were probed with sequences 
corresponding to the early replication origin ARS305 or flanking DNA (6Kb, 18Kb or 
29Kb towards the left telomere of chromosome III), where ARS301-304 are normally 
dormant. In these gels, a bubble arc reflects bidirectional origin firing and Y arcs result 
from the asymmetric movement of replication forks through the restriction fragment 
being probed. X-spikes accompany origin firing and decrease in intensity as forks 
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Fig. 4.4 TORC1 acts as a survival pathway in response to DNA damage by 
maintaining the dNTP pools 
When the S-phase checkpoint is activated by DNA damage, ribonucleotide reductase 
(RNR) is induced to maintain dNTP pools to for translesion of DNA synthesis and 
survival. RAP inhibition of TORC1 inhibits the induction of RNR subunits thereby 
decreasing levels of dNTP pools. 
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migrate (12). 
As shown in Fig. 4.5, after release into S-phase, firing of ARS305 was unaffected 
by rapamycin, as evidenced by a robust bubble arc at 10 minutes. Untreated cells 
continued to cycle: the bubble arc apparent after release from α-factor, was not detected 
at 60 minutes and reappeared at 180 minutes as cells entered subsequent cell cycles. The 
decrease in replication intermediates after 60 minutes of rapamycin treatment coincided 
with the accumulation of cells in G1 phase. With MMS, the accumulation of a strong Y 
arc and X-spike indicates slow fork progression at 30 minutes. The decrease in 
intermediates at 60 minutes coincided with fork progression and the accumulation of cells 
with a 2n DNA content. A slightly less intense pattern of replication intermediates was 
obtained with MMS + RAP at 30 minutes. However, the decrease in replication 
intermediates at 60 and 180 minutes, relative to MMS alone, did not correspond with 
increased DNA content. A persistent cell cycle arrest in early S-phase due to Rad53 
checkpoint activation would yield stable replication intermediates over the time course of 
these experiments. Rather these data suggest a decrease in fork stability. 
To directly assess these issues, we next assessed replication fork migration 
towards the left telomere of chromosome III in isogenic strains wild-type for the Rad53 
checkpoint or deleted for RAD53 (rad53∆). As shown in Fig. 4.6, similar blots of 
replication intermediates obtained from cells released from α-factor into MMS alone or 
MMS + RAP were successively re-probed with sequences 18Kb and 29Kb downstream. 
Replication intermediates isolated from MMS-treated rad53Δ cells demonstrated 
a more rapid progression of replication forks (relative to wild-type cells) with a strong Y 
arc detectable at +29Kb by 60 minutes and little evidence of fork collapse. The dormant 
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Fig. 4.5 MMS+RAP treatment diminishes replication fork stability 
At the times indicated following α-factor release into YPD, MMS, RAP, or MMS+RAP, 
replication intermediates were resolved in 2-D gels. The distribution of bubble arcs, Y 
arcs and X-spikes, which indicate origin firing, passive DNA replication and slow fork 
progression, respectively, was determined in southern blots with an ARS305 probe. 
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Fig. 4.6 Decreased fork stability induced by MMS+RAP treatment is Rad53-
independent 
Replication intermediates from wild-type and rad53Δ cells, released from α-factor into 
MMS or MMS+RAP, were resolved in 2-D gels. The blots were successively hybridized 
with probes derived from ARS305 and sequences 6Kb, 18Kb and 29Kb to the left of 
ARS305 on chromosome III (the reverse orientation is diagrammed). Dormant ARS301, 
302, 303 and 304 are in grey. 
of ARS305. In MMS-treated wild-type cells, replication intermediates evident at ARS305 
at 30 minutes, shifted to a strong Y arc at +18Kb by 60 minutes and had dissipated by 
180 minutes, indicating continued fork progression. Only weak Y arcs were detected at 
+29Kb. In contrast, the uniform decrease in Y arc signal along chromosome III seen in 
MMS+RAP treated cells (Fig. 4.6) and concomitant delay in S-phase transit (data not 
shown) indicated a decrease in fork stability. 
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ARS301 at +29Kb also fired in MMS treated rad53Δ strains, as previously reported (12). 
In contrast, the pattern of fork progression in rad53Δ cells treated with MMS+RAP 
resembled that obtained with wild-type cells. Thus, the decreased fork stability induced 
by MMS + RAP appeared to be Rad53-independent. We next asked if TORC1 only 
maintains fork stability in response to DNA damage or also functions in response to 
replicative stress, which does not involve translesion DNA synthesis. To address this 
question, we also isolated DNA replication intermediates from wild-type and rad53Δ 
cells treated with HU + or- RAP. 
 
4.3.3 TORC signaling promotes fork progression in response to HU-induced 
replication checkpoint activation 
As diagrammed in Fig. 4.2, the same experimental approach was also used to 
assess the consequences of inhibiting TORC1 signaling in the presence of HU. HU is a 
potent inhibitor of ribonucleotide reductase. Although HU treatment activates the 
Rad53checkpoint, this is a consequence of depleted dNTP pools inducing a slowing of 
replication fork progression, which in turn triggers the checkpoint. Allosteric feedback 
activation of ribonucleotide reductase holoenzyme activity ensures the production of 
sufficient dNTP levels to maintain cell viability and yeast cells can withstand prolonged 
exposure to HU without adverse affects on clonogenic survival. Since HU treatment does 
not produce frank DNA lesions, we asked if RAP inhibition of TORC1 signaling would 
adversely impact cell survival in the face of persistent replicative stress. 
As shown in Fig. 4.7, checkpoint activation by HU slowed S-phase transit; 
replication forks did progress, albeit at a reduced rate. And, as observed with MMS,  
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Fig. 4.7 TORC1 signaling promotes replication fork progression and maintains the 
viability of cells exposed to HU 
Replication intermediates from wild-type and rad53Δ cells, treated with HU or HU + 
RAP were resolved in 2-D gels and successively probed with sequences derived from 
ARS305, 305+6Kb and 305+18Kb. 
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TORC1 inhibition further diminished the S-phase transit of cells treated with HU. Yet, in 
stark contrast to MMS + RAP, the delay in cell cycle induced by HU + RAP resulted 
from a more pronounced decrease in the fork progression, without detectable alterations 
in fork stability. In HU treated wild-type cells, the ARS305 bubble arc accumulated at 60 
minutes, independent of rapamycin. The slow progression of the Y arc induced by HU 
(from +6Kb at 60 minutes to +18Kb at 180 minutes), was further delayed in the presence 
of HU + RAP (a strong Y arc persists at +6Kb at 180 minutes). These results contrasted 
with HU treatment of rad53Δ cells, which induced replication fork collapse, independent 
of TORC1 signaling. Thus, unlike the situation with the DNA damage induced by MMS 
treatment, in HU treated cells the inhibition of TORC1 signaling suppressed fork 
progression, while Rad53 functioned to maintain fork stability.  
However, when drug exposure was extended to 24 hours, cells treated with HU + 
RAP exhibited a persistent arrest in early S-phase, accompanied by a ~30-fold drop in 
cell viability (data not shown). In contrast, cells exposed to HU for 5-9 hours exhibited a 
late S/G2 phase DNA content, and by 24 hours most cells were in G1 phase with little or 
no loss of viability (data not shown). These findings suggest that TORC1 signaling is not 
only required to promote replication fork progression, but also functions to maintain cell 
viability in the presence of persistent replicative stress. Indeed, as shown in Fig. 4.8, HU 
treatment dramatically slows the progression of the replication forks that initiate at 
ARS305, such that a robust Y-arc is only detected at residues 18 Kb downstream from 
ARS305 after 3 hours following α-factor release. A weaker, yet persistent Y-arc is 
detected at 3-5 hours at +29 Kb. A weak bubble arc is also seen at 5 hours, indicative of a 
small percentage of cells entering the next cell cycle. These data are consistent with the 
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Fig. 4.8 TORC1 signaling is required for fork progression during persistent 
replicative stress 
Replication intermediates were isolated from cell released into media containing HU and 
HU + RAP, visualized using 2-D gel electrophoresis, blotted and probe for ARS305, 
ARS305 + 6Kb, ARS305 + 18Kb and ARS305 + 29Kb. Replication fork progression from 
ARS305 is dramatically slowed when cell are released into HU, in contrast, cells released 
into HU + RAP exhibit a persistent delay in fork progression.  
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FACs profiles obtained under the same conditions (data not shown). In contrast, a 
persistent delay in fork progression is obtained from HU+RAP treated cells. A robust 
bubble arc persists from 1 through 5 hours, followed by appearance of a robust Y-arc at 
more distal (+6Kb and +18 Kb) sites. However, consistent with the FACs profiles, a 
similar pattern of robust Y-arcs are not detected at +29 Kb. Taken together, these data 
suggest that TORC1 signaling is required for fork progression in the face of persistent 
replicative stress, but not to maintain fork stability. Nevertheless, this prolonged 
retardation of fork progression will ultimately impair cell viability.  
 
4.4 DISCUSSION 
Our findings revealed that rapamycin-sensitive TORC1 signaling functions to 
promote S-phase transit and maintain cell viability following Rad53 checkpoint 
activation by DNA damage or replicative stress. In response to MMS-induced DNA 
damage, TORC1 appears to exhibit Rad53 checkpoint dependent and independent 
functions. First, TORC1 signaling is required to sustain the DNA damage checkpoint- 
mediated induction of ribonucleotide subunits Rnr1 and Rnr3, thereby ensuring sufficient 
ribonucleotide reductase activity to generate the high levels of dNTPs necessary for 
translesion DNA synthesis to bypass MMS-induced DNA lesions. The regulation of 
translesion synthesis of DNA adducts by this mechanism could also explain the increased 
sensitivity of mammalian cells to cisplatin that is induced by rapamycin (68). Second, 
TORC1 signaling was also required to maintain replication fork stability, independent of 
the Rad53 checkpoint. Whether this phenotype results from a RAP-induced decrease in 
the translation of replication fork components has yet to be assessed. Nevertheless, these 
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findings support a model for the enhanced RAP sensitivity of cdc45-10 cells. The 
fragility of forks assembled in cdc45-10 cells at the non-permissive temperature, which 
suffices to slow S-phase transit and requires the S-phase checkpoint to maintain cell 
viability, would be exacerbated by RAP-induced fork collapse. Similar considerations 
would also hold for dpb11-10 cells. Indeed, the enhanced sensitivity of cdc45-10 and 
dpb11-10 cells to RAP was only observed at the non-permissive temperature. Whether 
the dosage suppressors defined in Chapter 2, or the SUMO site mutation in Cdc45 also 
impacts the RAP sensitivity of cdc45-10 cells has yet to be determined. 
The effects of RAP inhibition on TORC1 signaling in cells exposed to MMS-
induced DNA damage contrasted with that of cells exposed to HU. When cells are 
exposed to replicative stress, due to HU-induced depletion of dNTPs, fork stability was 
dependent on Rad53, not TORC1 signaling. In the face of prolonged exposure to HU, the 
forks are very stable; however, they fail to progress when TORC1 signaling is inhibited 
by RAP and the cells will eventually die. These data suggest that in response to DNA 
damage, RAP treatment impairs the activity of some factor or factors whose activity is 
required to maintain fork stability. However, in HU treated cells, this activity is either not 
required or is not affected by RAP and fork stability is maintained by Rad53. 
In response to MMS or HU treatment, RAP does induce the down regulation of Rnr1 and 
Rnr3 (data not shown) (53). In the case of MMS-induced DNA damage, the resultant 
decrease in dNTP levels effectively suppresses translesion DNA synthesis such that the 
mutagenic activity of MMS is repressed and cell viability is further compromised (53). 
HU does not induce mutagenic DNA lesions, so the consequences of Rnr1/3 down 
regulation are quite distinct. HU itself inhibits ribonucleotide reductase to partially 
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deplete intracellular levels of dNTPs. However, the enzyme is also subject to allosteric 
regulation such that a modest increase in activity provides sufficient dNTP levels to 
maintain cell viability, although fork progression is severely hampered (as seen in Fig. 
4.8). However, our findings suggest that the additional down regulation of Rnr1 and Rnr3 
by RAP inhibition of TORC1 further reduces ribonucleotide reductase levels, thereby 
effecting a much more severe depletion of dNTPs. In essence, the replication machinery 
becomes starved for dNTPs, the building blocks of DNA, and the fork stalling is more 
pronounced. In this case, Rad53 then plays a critical role in maintaining fork stability. In 
the face of prolonged replication stress, the cells will eventually die. Thus, TORC1 
signaling also functions as a survival factor in response to DNA damaging agents as well 
as prolonged replication stress. 
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CHAPTER 5: DISCUSSION 
 
Eukaryotic DNA topoisomerase I (Top1) acts as a swivel to remove positive and 
negative supercoils that accumulate during cellular processes such as DNA replication, 
recombination and transcription through a mechanism of transient DNA strand cleavage 
and religation (1,2). Top1 is a monomeric enzyme that forms a protein clamp around 
duplex DNA. The active site (Tyr727 in yeast) acts as a nucleophile to cleave the 
phosphodiester backbone of a single DNA strand, forming a covalent 3’ phospho-tyrosyl 
linkage with the DNA. The 5’ end of the DNA rotates within this covalent Top1-DNA 
complex about the nonscissile strand to relax the positive or negative supercoils. The 
5’OH of the cleaved strand acts as a nucleophile in a second transesterification reaction to 
resolve the Top-DNA intermediate and religate the DNA (1,2). 
Top1 is the sole cellular target of the anticancer agent camptothecin (CPT). CPT 
targets Top1 and intercalates between the ends of the cleaved strand, interacting with 
both the DNA and the enzyme, to prevent the religation step of the catalytic cycle thereby 
extending the life of the covalently linked Top1-DNA intermediate (70,71). These 
stabilized drug-enzyme-DNA intermediates are formed in all stages of the cell cycle; 
however the cytotoxic activity of CPT is S-phase dependent. There are two suggested 
mechanisms to explain this S-phase toxicity. First, biochemical and genetic data provide 
evidence that advancing replication forks collide with the stabilized CPT-Top1-DNA 
complexes to induce irreversible DNA lesions that trigger checkpoint activation and cell 
death (6). Second, recent single molecule studies using human Top1 and a CPT analog 
topotecan, suggests a second mechanism where drug binding of Top1-DNA complexes 
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induce the accumulation of positive supercoils in front of advancing replication forks that 
could in turn block fork progression resulting in fork collapse and lethal DNA lesions that 
induce cell death (8). Despite extensive study, remarkably little is known of the 
molecular interactions involved in converting the drug-enzyme-DNA complexes into 
DNA lesions that trigger checkpoint activation or the downstream pathways required for 
the resolution and repair of these lesions. 
The genetically tractable budding yeast, S. cerevisiae, has been extensively used 
to study cellular processes such as DNA replication and the mechanism of cancer 
therapeutics (29) as most basic cellular processes, cell cycle machinery and mechanism 
of cell sensitivity and resistance to CPT are highly conserved from yeast to human.  
Using S. cerevisiae as a model system, a genetic screen was designed to isolate 
conditional temperature sensitive mutants that exhibit enhanced sensitivity to the CPT 
mimetic, Top1T722A. This self-poisoning enzyme exhibits a decrease in the rate of DNA 
religation. Yeast cells can tolerate low-level expression of this enzyme making it a 
valuable tool for identifying gene products and pathways that mediate cellular responses 
to CPT, while avoiding the complication of drug uptake and efflux. From this genetic 
screen, ten recessive tah mutants were identified. These mutants were unable to survive 
the damage induced by Top1T722A at 36˚C due to the loss or decrease of TAH gene 
product function. The tah mutants function in a variety of cellular pathways. One TAH 
gene identified, UBC9, encodes the sole E2 conjugating enzyme in the SUMOylation 
pathway. Three of the TAH genes are essential for DNA replication. CDC45 encodes a 
DNA replication initiation factor that is essential for the initiation and elongation steps of 
DNA replication. DPB11 encodes a subunit of the DNA polymerase II epsilon (ε) 
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complex that is essential for the loading of DNA polymerases to initiate DNA synthesis 
and is required for the S-phase checkpoint. TAH11 encodes a DNA replication licensing 
factor required for pre-replicative complex formation (5).  
The tah mutant cdc45-10 has a single amino acid substitution (G510R). These cells 
are hypersensitive to Top1T722A expression at 36˚C and transiently accumulate in early 
S-phase when shifted to 36˚C due to a defect in Okazaki fragment maturation. cdc45-10 
cells also exhibit a slow growth phenotype when RAD9 is deleted suggesting that the 
damage accumulating in these cells is sensed by the Rad9 DNA damage checkpoint. 
cdc45-10 exhibits a synthetic lethal interaction with another tah mutant, dpb11-10, which 
coincides with a persistent accumulation of Okazaki sized DNA fragments. Despite 
extensive study, the function Cdc45 during the initiation and elongation steps of DNA 
replication has yet to be defined. Our results imply that Cdc45 functions normally to 
protect cells against Top1-DNA damage. Therefore, further characterization of the 
replication defects in cdc45-10 cells would provide insights into the molecular 
interactions required to protect cells against Top-induced DNA damage. 
 
5.1 CDC45 HAS TWO DISTINCT FUNCTIONS 
Isolation of cdc45-10 as a hypomorphic allele exhibiting enhanced sensitivity to 
Top1T722A suggests that Cdc45 normally functions to protect cells against Top1-induced 
DNA damage. Increased gene dosage of this mutant allele restored cellular resistance to 
low-level expression of Top1T722A at 36˚C, however, failed to suppress the synthetic 
lethality of cdc45-10,dpb11-10 cells. These results suggested that the essential function 
of Cdc45 needed to protect cells from Top1 poisons is distinct from the functional 
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interactions that are essential to maintain cell viability and Okazaki fragment maturation. 
The alterations observed in cdc45-10 could not be attributed to thermolability of the 
protein as steady state protein levels of Cdc45G510R in asynchronus cultured mirrored 
those of Cdc45. In addition, the results obtained in the cdc45-10 high copy suppressor 
screen also suggested two distinct functions of Cdc45. The dosage suppressors isolated 
complemented cdc45-10 cell sensitivity to Top1T722A but failed to restore cell viability to 
the cdc45-10,dpb11-10 double mutant strain at 36˚C. These two distinct functions of 
Cdc45 is further supported by the results obtained from our attempts to epitope tag 
Cdc45. Incorporating an HA tag at the C-terminus of Cdc45 resulted in a protein that 
could maintain cell viability in plasmid shuffle assays, however, failed to complement the 
synthetic lethality of the cdc45-10,dpb11-10 double mutant strain. In contrast, 
incorporating a C-terminal HA tag on cdc45-10 resulted in a protein that could not 
maintain cell viability suggesting that the C-terminus of Cdc45 functionally interacts with 
the residues spanning Gly510 such that modifying the C-terminus results in a lethal 
protein. With the exception of a bipartite nuclear localization signal, the amino acid 
sequence of Cdc45 does not predict similarities with any known domains. Therefore, 
having the X-ray structure of Cdc45 would provide a means of visualizing the functional 
interaction between the C-terminus of the protein and region spanning the Gly510. 
 
5.2 DOSAGE SUPPRESSORS OF cdc45-10 SUGGEST DISTINCT DEFECTS 
Increased gene dosage of cdc45-10 suppressed the hypersensitivity of the cells to 
Top1T722A at 36˚C, but not the synthetic lethality of cdc45-10,dpb11-10 cells. To define 
pathways specific for cellular resistance to Top1 poisons, we used a yeast genetic screen 
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to identify extragenic dosage suppressors of cdc45-10 sensitivity to Top1T722A. The 
characterization of the two dosage suppressors isolated suggested distinct defects in 
Cdc45G510R. The first suppressor, ARS1303, is an origin of replication located on 
chromosome XIII. Isolation of this suppressor suggests a defect in origin licensing or 
firing in cdc45-10 cells. This dosage suppressor also complemented the tah phenotype of 
dpb11-10 and tah11-10, which are also essential during DNA replication. To date, very 
little information is available for ARS1303, therefore, determining if this ARS sequence 
normally fires during S-phase and the temporal pattern of this firing would provide 
valuable information to further characterize this dosage suppressor. Furthermore, 
determining if other ARS sequences such as ARS305 or ARS309 could dosage suppress 
cdc45-10, dpb11-10 or tah11-10 would determine if ARS1303 is a unique ARS sequence 
with distinct dosage suppressor function or if simply increasing the number of origins on 
a plasmid increases the likelihood of at least one origin firing per cell and therefore 
contributes to the stability of the plasmid in the cell. 
The second dosage suppressor, SIZ1, encodes a gene product that functions in the 
SUMOylation pathway as an E3 ligase. This suppressor restored cell viability to cdc45-
10 and ubc9-10 in the presence of Top1T722A at 36˚C suggesting that SUMO 
modification of target proteins is required to protect cells from Top1 poisons. The amino 
acid sequence of Cdc45 revealed one consensus SUMO site, however, mutating the 
consensus SUMO site in Cdc45 did not alter cell sensitivity to CPT or HU at 36˚C, but 
mutating this same site in cdc45-10 enhanced the temperature sensitivity and CPT and 
HU sensitivity at 36˚C. Moreover, Cdc45SUMO did not restore cdc45-10,dpb11-10 cell 
viability. Altogether, these results suggest that mutating this site has no effect on the drug 
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sensitivity of Cdc45, but does alter the essential function of Cdc45 needed for the 
interaction with Dpb11. Therefore, determining if Cdc45 is a target for SUMO 
modification and if this modification is altered in Cdc45SUMO or cdc45-10 may provide 
insight into the defects that alter the essential function of these proteins. Furthermore, 
since Cdc45 is a scaffolding protein that interacts with many different components of the 
replication machinery, immunoprecipitation assays can be utilized to determine defects in 
Cdc45SUMO and cdc45-10 binding to known interacting proteins such as Dpb11 or Mcm5. 
  
5.3 CDC45 FUNCTION IS REQUIRED FOR TIMELY ORIGIN FIRING AND 
APPROPRIATE ASSEMBLY OF REPLICATION MACHINERY 
Cdc45 is essential for initiation and elongation during DNA replication, therefore 
assessing origin firing and replication fork progression in cdc45-10 cells identified the 
alterations evident in these cells. We utilized two distinct experimental approaches to 
address defects occurring in the licensing step (G1) or the initiation and elongation steps 
(S-phase). The first approach was to synchronize cultures in late G1 at the permissive 
temperature release the cells into S-phase at the non-permissive temperature. This would 
permit licensing to occur at the permissive temperature, while replication would occur at 
the non-permissive temperature. Under these conditions cdc45-10 cells exhibited a 
decrease and delay in origin firing at ARS305, however, replication forks progressed with 
kinetics similar to wild-type suggesting that Cdc45G510R cells were defective in the 
initiation step only. This cdc45-10 phenotype was not the result of a thermolabile 
Cdc45G510R protein as we observed an increase in Cdc45G510R steady state protein levels 
compared to wild-type when cells were released into S-phase at 36˚C. These results 
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imply that the replication defects in cdc45-10 cells is not the consequence of Cdc45G510R 
down regulation when cells are shifted to 36˚C.  
The second approach was to culture cdc45-10 at 36˚C prior to G1 arrest where 
licensing and replication would be carried out at the non-permissive temperature. Under 
these conditions replication forks appeared to be distributed along a linear diagonal with 
a DNA mass between 1n and 2n implying that DNA replication had initiated at ARS305, 
however, the intermediates isolated were fragile and collapsed upon purification. As in 
the previous experiment, the protein levels of Cdc45G510R in the cells cultured at 36˚C 
were also elevated in S-phase compared to Cdc45. Altogether these results indicate that 
origin licensing in cdc45-10 cells at 36˚C altered the assembly of stable replication forks 
in subsequent S-phase such that they collapse upon purification, while the assembly of 
pre-RC complexes at 26˚C, followed by S-phase progression at 36˚C, only affected the 
temporal pattern and efficiency of origin firing in cdc45-10 cells. 
Cdc45 has been shown to be a scaffolding protein that interacts with components 
of the replication machinery including Dpb11, Mcm5 and the GINS complex. Therefore, 
determining if Cdc45G510R is defective in binding to any of the known interacting 
proteins may provide an explanation for the alterations observed in replication fork 
stability. The development of an antibody capable of immunoprecipitating Cdc45G510R 
will provide the answers to these questions. 
 
5.4 RAPAMYCIN-INDUCED ALERATIONS IN S-PHASE TRANSIT 
A yeast genetic screen was designed to isolate conditional mutants exhibiting 
enhanced sensitivity to the self-poisoning Top1T722A (5). Surprisingly, several of these 
113 
mutants were also hypersensitive to the macrocyclic lactone antibiotic rapamycin (RAP), 
including CDC45 and DPB11 (53). RAP, in complex with FKBP12, specifically targets 
TOR (target of rapamycin), a phosphatidylinositol 3-kinase-related kinase family member 
that regulates cellular responses to a wide range of environmental stresses such as 
nutrient starvation, growth factor deprivation and hypoxia. These signals are transmitted 
by multi-protein complexes through a variety of downstream pathways to regulate cap-
dependent mRNA translation, transcriptional stress responses, G1 to S-phase transition 
and cell survival (55,57,58). Several reports including our report that CDC45 and DPB11 
are sensitive to RAP, implies a role for TOR signaling in S-phase, as these hypomorphic 
alleles are essential for the initiation and elongation steps during DNA replication 
(65,66). 
In yeast cells, RAP inhibition of TOR signaling induces cell cycle arrest in early 
G1. This arrest precedes the G1 block induced by α-factor (69) providing a means for 
assessing TOR signaling in S-phase. When cells were released into media containing 
RAP, a subpopulation of α-factor arrested cells did not transit S-phase, however, the 
kinetics of S-phase transit for those cells that did enter S-phase were similar those of the 
untreated control cells with RAP-treated cells accumulating in the next G1 phase. When 
cells were released into media containing MMS, S-phase transit was slowed due to the 
activation of the Rad53 checkpoint.  In contrast, when cells were treated with MMS + 
RAP a further delay in the slow S-phase transit was observed. RAP treatment alone is 
growth inhibitory not cytotoxic. However, MMS treatment is cytotoxic and this 
cytotoxicity is enhanced when cells are co-treated with RAP + MMS which is evident by 
a proportional decrease in colony number that we observed over time. 
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We previously reported that TORC1 signaling is required to maintain the elevated 
expression of the ribonucleotide reductase subunits, Rnr1 and Rnr3, to maintain dNTP 
pools for tranlesion synthesis and survival in response to genotoxic stress (53). The 
results observed in the MMS+RAP treated cells suggested a role for TORC signaling in 
stabilizing replication forks in cells exposed to DNA damage. Using 2-D gel analysis we 
assessed origin firing and fork stability in cells treated with MMS +/- RAP. RAP 
treatment did not affect origin firing at ARS305 and cells moved through S-phase with a 
subpopulation accumulating in the subsequent G1 phase. MMS treated cells exhibited 
slow fork progression, however, these cells did accumulate a 2n DNA content. A slightly 
less intense pattern of replication intermediates was obtained with MMS + RAP 
treatment suggesting a decrease in replication fork stability. To determine if these results 
were dependent on the Rad53 checkpoint pathway, the same experiments were conducted 
in cells lacking Rad53 (rad53Δ). Replication intermediates isolated from MMS-treated 
rad53Δ cells demonstrated a more rapid progression of replication forks compared to 
wild-type with little evidence of fork collapse. The cryptic origin ARS301 fired in these 
cells as previously reported (12). When rad53Δ were treated with MMS + RAP the 
pattern of fork progression observed was similar to that of wild-type suggesting the 
decrease in fork stability induced by MMS + RAP appeared to be Rad53-independent. 
To determine if TORC1 also functions in response to replicative stress, replication 
intermediates were isolated from wild-type and rad53Δ cells treated with HU +/- RAP. 
HU treatment results in inhibition of ribonucleotide reductase causing a depletion of 
dNTP pools and activating the Rad53 checkpoint to inducing a decrease in replication 
fork progression. Sufficient dNTP levels are produced to maintain cell viability due to 
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allosteric feedback activation of ribonucleotide reductase holoenzyme activity. This 
allows cells to withstand prolonged exposure to HU without adverse affects on cell 
viability. HU treated cells exhibited a slowed S-phase transit due to checkpoint 
activation, however, the replication forks did progress. Similar to MMS treatment, cells 
treated with HU + RAP exhibited a further delay in S-phase transit. In contrast to MMS + 
RAP, the HU + RAP treated cells exhibited a more pronounced decrease in the fork 
progression, without affecting fork stability. HU treatment of rad53Δ cells resulted in 
replication fork collapse and this was independent of TORC1 signaling. Therefore in HU 
treated cells the inhibition of TORC1 signaling suppressed fork progression, while Rad53 
functioned to maintain fork stability. When cells were exposed to replicative stress for an 
extended period of time (HU at 24 hours), no decrease in cell viability was observed. In 
contrast, when cells were treated with HU + RAP for 24 hours an arrest in early S-phase 
with a decrease in cell viability was observed. Together these findings suggest that 
TORC1 signaling is required to promote replication fork progression and also functions 
to maintain cell viability in the presence of persistent replicative stress. 
In this study, we suggest two independent functions of TORC1 signaling in S-
phase. First, TORC1 signaling functions to promote S-phase transit and maintain cell 
viability following Rad53 checkpoint activation by DNA damage or replicative stress. 
Second, TORC1 signaling is also required to maintain replication fork stability, 
independent of the Rad53 checkpoint. One consequence of RAP inhibition of TORC1 
signaling is a decrease in protein translation, therefore analyzing mRNA and protein 
levels of the replication fork components in cells treated with RAP will provide evidence 
as to the exact defects observed as a result of RAP treatment.  
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Our studies suggest a model for the enhanced RAP sensitivity of cdc45-10 and 
dpb11-10 cells. This enhanced sensitivity to RAP occurred at the non-permissive 
temperature only, which corresponds to the observation of fragile replication forks in 
cdc45-10 cells at 36˚C. Therefore, determining if treatment of these cells with RAP 
exacerbates this phenotype by inducing fork collapse would determine if our model is 
correct. In addition, determining if the suppressors isolated in the cdc45-10 high copy 
suppressor screen, or the Cdc45SUMO or Cdc45SUMO, G510R mutants alter cdc45-10 
sensitivity to RAP will further characterize the defects observed in these cells. 
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